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Abstract 
Pesticide use in the United States continues to attract negative public attention. In 
recent years, this attention has focused on the effects that chronic, low-level pesticides 
may have, especially on children and various sub-populations.  Over the past decade, 
studies have attempted to correlate negative health effects with detections of pesticide 
biomarkers in biological media.  The current research investigates biomarker of exposure 
levels in a sample of the United States population.  Data from the 2001-2002 NHANES 
dataset (n=11,039) was evaluated.  The detection frequency of urinary biomarkers of 
exposure and the geometric mean from the NHANES pesticide dataset (n=3,152) were 
determined.  Of the 18 specific pesticide biomarkers, three were detected in more than 
50% of the sample: 79% had a detectable level of 3,5,6-trichloropyridinol, a biomarker of 
chlorpyrifos, with a geometric mean of 2.07 µg/L (C.I: 1.98-2.17); 53% had a detectable 
level of  paranitrophenol, a biomarker of methyl parathion, with a geometric mean of 
0.367 µg/L (C.I.: 0.346-0.389); and 77% had a detectable level of  3-phenoxybenzoic 
acid, a biomarker of permethrin, with a geometric mean of 0.336 µg/L (C.I.: 0.320-
0.352).  These levels fall within the range of other epidemiological and biomonitoring 
studies investigating background levels of biomarkers in the general population.  The 
association between the detection of a biomarker and variations in mean height and 
weight of children aged 6-11 was evaluated.  No significant results were found when 
evaluating these differences for 3,5,6-trichloropyridinol exposure. Paranitrophenol 
 
 
xv 
associated with shorter children at age 8 [Non-Detect=134.3 cm and Detect: 130.9 cm 
(p=0.046)] and taller children at age 11 [Detect=153.7 cm and Non-Detect=149.9 cm 
(p=0.022)].  Heavier children associated with 3-Phenoxybenzoic Acid at age 7: 
[Detect=28.61 kg and Non-Detect=25.26 kg (p=0.009)].  Clinical chemistry biochemical 
concentration comparisons were made between individuals that had a detectable level of 
the biomarker in urine and those that did not.  Two biochemicals had a significant 
difference across all three biomarkers: cholesterol and sodium.  The biochemical levels 
with significant difference between detects and non-detects for the biomarkers were not 
elevated above clinical reference values.  Overall, there is insufficient evidence to suggest 
a relationship between background pesticide exposures in this sample and negative health 
effects. 
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Chapter 1 
Introduction 
Public health concerns surrounding the use of pesticides have been a major focus 
of the United States Environmental Protection Agency (EPA) and the United States Food 
and Drug Administration (FDA) for decades.  Research conducted around World War II 
led to the refinement and discovery of new, inexpensive and effective pesticide products 
[1, 2].  These new discoveries began to replace the inorganic substances (copper 
acetoarsenite, sodium chlorate, sulfur) that had been used previously [1, 2].  Consumers 
in the 1950’s did not appear to be concerned with any potential hazards these new 
pesticides may pose, and consumers in the 1960’s were more concerned with the impact 
that pesticide use had on wildlife than the impact that pesticides had on farmers [2, 3].  
This emerging concern originated from the publication of Rachel Carson’s Silent Spring 
in 1962 which highlighted the potential environmental dangers of pesticides [1, 2, 3].  
Public concern now became focused on the possible detrimental effects pesticide use was 
having on the environment. While the quality of the research and the conclusions reached 
in Silent Spring have been called into question, the work has been credited with the 
initiation of the modern environmental movement [4, 5]. 
 
Public concern over pesticide use was, in part, responsible for the focus on 
regulating the use and application of pesticides in the United States.  The potential 
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deleterious effects that pesticides may have on the environment, and on members of the 
population, spawned a new effort to regulate their use [6-12].  
 
Regulatory agencies began to conduct research into potential exposures to 
pesticides and determine what might be considered safe exposure levels (i.e., no 
appreciable increased risk of a deleterious effect).  While decades of research have 
established putative mechanisms for deleterious effects associated with acute, high-level 
exposures, very little evidence exists to support effects from chronic, low-level 
exposures. Studies in recent years have attempted to characterize the contribution of 
chronic, low-level pesticide exposures to birth defects, most notably neurological, 
behavioral and birth outcomes.  The research conducted in the current study will utilize 
urinary biomarker data gathered during a National Health and Nutrition Examination 
Survey (NHANES) national sampling event to determine if chronic, low-level exposure 
to pesticides can be associated with an increased risk of adverse health outcomes.  
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The objectives of the current study are as follows: 
• Characterize low-level exposures in a sample of the general population of the 
United States. 
• Determine mean concentrations of biomarkers of exposure levels in the sample 
and compare those levels to determine if any subgroup is at an increased risk of a 
toxicological outcome. 
• Examine the feasibility of establishing a biomarker of exposure threshold level 
based on the concentration of urinary biomarkers of exposure. 
 
This study will attempt to test the following hypotheses: 
1. Biomonitoring data obtained from NHANES indicate the presence of background 
biomarkers of exposure in individuals from a sample of the general population. 
2. Mean concentrations of biomarkers of exposure are homogeneous across the 
various subgroups of the sample, indicating that no one subgroup is at an 
increased risk of an adverse health outcome.  
3. Urine sample data from NHANES reveal that biomarker of exposure levels in the 
sample are not correlated with an increased risk of a negative health outcome.  
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Chapter 2 
Literature Review 
Pesticides encompass a large group of chemicals that are used for preventing, 
destroying, repelling or mitigating pests [13].  This category includes, but is not limited 
to, insecticides, fungicides, herbicides and rodenticides [14].  A variety of products are 
available for eliminating or mitigating pests in both residential and agricultural settings.  
For the purposes of this dissertation, the pesticides being evaluated are listed in Table 1. 
Table 1: Pesticides Included In This Research. 
 
Parent Compound Pesticide Type 
Chlorpyrifos Organophosphate Insecticide 
Methyl Parathion  Organophosphate Insecticide 
Permethrin Pyrethroid Insecticide 
 
2.1 Pesticide Use 
On a global scale, approximately $39 billion dollars were spent on pesticides in 
2007, with $12.5 billion dollars spent in the Unites States (US) alone [15].  This equates 
to the use of 5.2 billion pounds of pesticide’s active ingredients globally, with 1.1 billion 
pounds used in the US (Figure 1) [15].  These active ingredients are used to create the 
more than 20,000 EPA registered pesticides currently available in the US [16]. 
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Figure 1: Pesticide Type By Sector. This breakdown from the EPA 2007 market estimate 
indicates that agricultural applications of herbicides dominate the market. Figure from the 
EPA [14]. 
 
2.2 Regulations 
Federal regulations have been established by the federal government in an attempt 
to make the use and application of pesticide products safe for the end user. The first 
federal pesticide legislation in the US was the Insecticide Act of 1910 [13].  This Act set 
standards to protect consumers from misbranded or impure pesticides [17, 18, 19].  The 
Federal Food, Drug and Cosmetic Act (FFDCA) of 1938 allowed for the establishment of 
regulatory limits for pesticide residues in food [19].  The Federal Insecticide, Fungicide 
and Rodenticide Act (FIFRA) of 1947 required all pesticides being sold interstate or to 
foreign entities to be registered with the US Department of Agriculture [18].  It also 
required the identification labels on containers to carry information about the 
manufacturer of the pesticide, the ingredients, directions for use and a protective warning 
statement [18].  FIFRA was amended in 1959 and 1964 to include additional pesticides.  
In addition, the 1964 amendment gave authority to the Secretary of Agriculture to refuse 
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registration of a new pesticide or cancel an existing registration if the pesticide was 
thought to pose a hazard [17, 18]. 
 
The 1954 Miller Amendment to the FFDCA established pesticide residue 
tolerances and required the seizure of raw agricultural commodities if they contained 
residues above established tolerance levels [18, 19].  The Delaney Clause, part of the 
Food Additives Amendment (FAA) of 1958, prohibited the use of a food additive if it 
was shown to be carcinogenic in humans or laboratory animals [18, 19, 20].  The 
responsibility of the amended FIFRA was transferred to the EPA at the agency’s 
inception in 1970 [21].  This transfer of power was a paradigm shift from creating safe 
user conditions in agricultural settings to reducing risk from pesticides in the general 
population and the environment [22].  FIFRA was amended in 1972 with the passage of 
the Federal Environmental Pesticide Control Act (FEPCA) [21-23].  
 
The FEPCA required all pesticides to be registered with the EPA and required the 
pesticide to be classified as general use or restricted use [22].  Under this Act, 
certification was now necessary for those applying restricted use pesticides and pesticides 
would now only be registered if they could be demonstrated to not cause unreasonable 
harm to the environment [22].  In 1996, the FFDCA was amended with the Food Quality 
Protection Act (FQPA).  The FQPA called for the review of all current maximum residue 
levels of pesticides on food and added the requirement that infants and children must now 
receive additional protection and focus [24].  The Act also called for an aggregate and 
cumulative risk assessment for non-occupational exposures to pesticides [24]. 
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2.3 Exposure Assessment 
 Exposure is the opportunity to contact a substance and absorb a dose [14].  
Exposure assessment determines the chemical encountered, the route of exposure, and the 
magnitude, frequency and duration of the exposure [24].  Assessment methods vary based 
upon the type of exposure.  Occupational exposure evaluations consist of sampling the air 
surrounding the breathing zone, skin wipe samples or ambient air monitoring to 
determine an exposure level [25].  In occupational settings, a more sensitive and specific 
metric for establishing an exposure is to conduct biomonitoring as part of a workplace 
medical surveillance program [26].  
 
2.4 Biomonitoring 
Biomonitoring is the sampling of biological media (blood, urine, tissue, breast 
milk) for any chemical that may have been absorbed into the body during an exposure 
[27-32].  History points to the use of biomonitoring for the evaluation of workplace 
exposures in the 1920’s and 1940’s with the examination of blood for the presence of 
lead as well as examining mercury levels in urine [32].  In 1987, the National Research 
Council (NRC) established three distinct categories for biological markers to be used for 
the evaluation of an exposure: biomarkers of exposure, biomarkers of effect and 
biomarkers of susceptibility [28, 31, 32].  Biomarkers of exposure are detectable levels of 
a parent chemical compound, intermediate biomarker or conjugate in body tissue or 
biological fluids [29, 32, 33].  Biomarkers of effect are changes in clinical chemistry 
levels or other biochemical levels that can quantitatively or qualitatively predict an 
adverse health outcome or an impairment from an exposure [28].  Biomarkers of effect 
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are used to determine early biological or physiological alterations caused by an exposure 
to a chemical or substance [32].  Alteration in biochemical enzymes or formation of 
deoxyribonucleic acid (DNA) adducts due to an exposure would be considered 
biomarkers of effect.  Lastly, biomarkers of susceptibility indicate how an exposure 
might have an effect based on certain metabolic characteristics of an individual or a 
population [28, 31].  
 
Biomonitoring provides a measurement of exposure from all routes [30, 32].  
Detection of biomarkers in biological media can be influenced by the half-life of a 
chemical in vivo, physical characteristics of the chemical itself and the detection limit of 
the biomarker in body tissues and fluids by the laboratory conducting the analysis [26, 
30, 34].  In order to properly evaluate biomonitoring data, the toxicokinetics of the 
chemical must be understood [35].   
 
Biomonitoring can be used in the workplace.  Occupational biomonitoring is 
commonly a step in an overall health surveillance program [36].  The program begins 
with a base-line evaluation that is followed by periodic monitoring to determine if there 
are any exceedances of established threshold limits [36].  While biomonitoring programs 
in occupational settings have become more commonplace in recent years, and more 
accurate due to advances in detection, biomonitoring can also be utilized for establishing 
exposure in the general population [29].  
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Population-based studies utilizing biomarker levels in biological samples have 
attempted to evaluate exposure and to identify any public health trends in order to 
determine if public health control measures have been effective [32].  Large population 
based studies evaluating pesticide exposures include: The German Environmental Study 
(GerES); The Center for the Health Assessment of Mothers and Children of Salinas 
(CHAMACOS); The National Health and Nutrition Examination Survey (NHANES); the 
Netherlands Generation R study; and the Children’s Pesticide Exposure Survey (CPES) 
of Washington State and Georgia [37-41].  Smaller, localized studies on pesticide 
exposures have also been conducted. 
 
2.5 Pesticide Exposures 
2.5.1 Occupational Exposure 
Agricultural workers, exterminators and pesticide manufacturing employees 
encounter high exposures to pesticides due to their trade and, thus, are at the highest risk 
for a biologically significant pesticide overexposure in the workplace [42-44].  It is 
estimated that approximately 2-2.5 million workers come in contact with pesticides 
annually as a result of their employment [45, 46].  Dermal contact and inhalation are the 
primary routes of exposure in occupational settings [47].  The National Institute for 
Occupational Safety and Health (NIOSH) Sentinel Event Notification System for 
Occupational Risk (SENSOR) program monitors occupational illnesses and injury in 
participating states [44, 48].  SENSOR data analyzed by Calvert (2008) indicated that, 
between 1998 and 2005, approximately 3,200 acute occupationally exposed pesticide 
related illnesses were reported in 10 states [42].  Other identified estimates vary on the 
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actual number of annual occupational exposures to pesticides.  Geer et al. (2004) reported 
EPA estimates in 1992 that suggested 10,000-20,000 acute occupational excessive 
exposures occur annually [49].  Occupational excessive exposures may vary depending 
on a number of factors: The type of pesticide used, the amount used, the route of 
exposure and the frequency and duration of the exposure to the pesticide [42, 43, 50].  
Additional factors when evaluating an occupational exposure to pesticides include: the 
proper use of personal protective equipment (PPE), proper application of the product, 
proper training for use, accidental spillage, soiled clothing and the concentration of the 
pesticide in solution, among others [43, 50, 51].  
  
Occupational exposure threshold limits have been established to protect the health 
of workers [52].  These limits attempt to protect the worker in exposure situations.  
Regulatory occupational exposure limits (OELs) are enforceable by law whereas 
authoritative OELs are suggestions by credible organizations [52].  It is important to note 
that these regulations are intended to protect worker health.  They do not, however, 
predict whether or not an adverse health outcome will occur if an exposure exceeds the 
threshold value [14].  Additionally, occupational pesticide exposures are augmented by 
the EPA Worker Protection Standard, which adds additional margins of safety for 
employees from occupational exposures to agricultural pesticides [45].  
 
The Occupational Safety and Health Administration (OSHA) publishes 
regulatory, enforceable Permissible Exposure Limits (PELs) in order to protect worker’s 
health [53].  NIOSH is responsible for the non-regulatory Recommended Exposure 
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Limits (RELs) [54].  The American Conference of Governmental Industrial Hygienists 
(ACGIH) publishes both the non-regulatory Threshold Limit Values (TLVs) and 
Biological Exposure Indices (BEIs), which can be used in conjunction with each other 
[55].  Not all chemicals have an established BEI. Exposures below the TLV are not 
expected to result in exceedances of established BEIs.  The regulatory and authoritative 
OELs for the pesticides covered in this research are listed in Tables 2 and 3. 
 
Table 2: Occupational Exposure Limits. 
 
Pesticide  
PELa  (mg/m3)b RELc (mg/m3) TLV
d 
(mg/m3) 
TWAe STELf TWA STEL TWA 
Chlorpyrifos None None 0.2 0.6 (skin) 0.1 
Methyl Parathion None None 0.2 (skin) None 0.02 
Permethrin 5.0 (pyrethrum) None 
5.0 
(pyrethrum) None 
5.0 
(pyrethrum) 
a(PEL) = Permissible Exposure Limit, enforceable by OSHA; b(mg/m3) Milligrams per 
Cubic Meter; c(REL) = Recommended Exposure Limit, published by NIOSH; d(TLV) = 
Threshold Limit Value, published by ACGIH; e(TWA) = Time Weighted Average, Based 
on an 8-Hour Work Day, 40 Hours a Week; f(STEL) = Short-Term Exposure Limit, 
Based on a maximum 15 Minute Exposure Average. [53-55] 
 
To establish exposure status, occupational exposure assessments can use either 
direct sampling methods or modeling [52].  As part of a medical surveillance program, 
biomonitoring can aid in determining an exposure and identifying trends.  This includes 
establishment of a baseline biomarker of exposure (BOE) level and annual or periodic 
monitoring of biomarkers in conjunction with a physical examination [36].  
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Table 3: Occupational Biological Monitoring Exposure Limits. 
 
Parent Biological Exposure Indices (BEI) 
Chlorpyrifos 70% AChEa of Baseline 
Methyl Parathion 70% AChE of Baseline;         0.5 mg/gb for Parathion 
Permethrin None 
a(AChE) = Acetylcholinesterase; b(mg/g) Milligrams per Gram. ACGIH BEI [55]. 
 
2.5.2 Residential Exposure 
Individuals that are exposed to pesticides outside of an occupational setting are 
considered general population exposures. Exposures in the general population can be 
secondary and are generally orders of magnitude lower than occupational exposures [56].  
In 2007, domestic use of pesticides accounted for 8 percent of the total conventional 
pesticides used in the United States [15].  Widespread pesticide use in the United States 
has equated to ~94,000 reported pesticide exposures in 2008, according to the American 
Association of Poison Control Centers’ National Poison Data System’s 26th annual report 
[57].  This value indicates the number of individuals in the population with suspected 
pesticide exposures.  Public concern has, in part, driven the interest relating to regulation 
and mitigation of public and environmental contact with these substances [6, 7, 11].  
 
Residential exposures occur through a variety of sources: handling and 
application of pesticides in home and garden settings; residues remaining on surfaces in 
the home following residential application of pesticide products; food and drinking water 
that contain pesticide residues; and aerosol drift and take-home exposure from either 
pesticide applications in close proximity to the home or from family members 
transporting residues home on soiled or contaminated clothing [50, 56, 58-63].  It has 
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been suggested that ingestion of food products containing pesticides is the primary route 
of exposure for the general population [64-67].  
 
The FQPA of 1996 called for the safety evaluation of pesticides based on all 
routes of exposure from non-occupational sources [68, 69].  Additionally, the EPA is 
required to address the risks pesticides may pose to infants and children.  This act also 
required the re-assessment of pesticide tolerance levels in food products.  Based on the 
FQPA and the National Academy of Science, the EPA established maximum residue 
levels on food products that vary by commodity [70].  As an additional evaluation of risk, 
the Agency for Toxic Substances and Disease Registry (ATSDR) has established 
Minimal Risk Levels (MRL).  The MRL (Table 4) is an estimate of the acceptable daily 
exposure that is likely to be without an increased appreciable, non-cancer risk [71].  The 
ATSDR MRL was established to evaluate exposures and potential health effects at 
hazardous waste sites, but can also be used as an evaluation/screening tool for exposures 
in the general population [71].  
 
Table 4: Oral MRLs from the ATSDR. 
 
Parent Acute Intermediate Chronic 
Chlorpyrifos 0.003 mg/kg/day a 0.003 mg/kg/day 0.001 mg/kg/day 
Methyl Parathion NA 0.0007 mg/kg/day 0.0003 mg/kg/day 
Permethrin 0.3 mg/kg/day 0.2 mg/kg/day NA 
a(mg/kg/day) Milligrams per Kilogram per Day. These thresholds are based on a 
milligram per kilogram per day (mg/kg/day) ingestion rate [71] 
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2.6 Pesticides 
 As previously noted, pesticides encompass a large group of chemicals aimed at 
mitigating or destroying pests.  Pesticide use has been receding since reaching a plateau 
in the 1980’s, as can be viewed in Figure 2 [13].  This reduction has been, in part, 
attributed to the manufacture of more efficacious compounds and the establishment of 
Integrated Pest Management (IPM) systems in developed countries [13].  Mechanisms of 
toxicity for the pesticides investigated in this study are similar for both pests and 
mammals [13, 22].  Precautions must be taken to reduce the chance for an overexposure 
to pesticide products.  The two main categories of pesticides that will be covered by this 
research, organophosphates and pyrethroids, will be detailed in the following sections.  
 
2.6.1 Organophosphate Insecticide 
In 2007, organophosphates (OP) accounted for 35% of all insecticides used in the 
US (33 Million Pounds) [15].  OP were originally synthesized in the 1800’s, but their 
refinement for pest mitigation did not occur until the late 1930’s and early 1940’s [13, 
72].  OP are readily degraded in the environment by way of hydrolysis, photolysis or 
biodegradation [73, 74].  There is little evidence to suggest that OP bioaccumulate in 
body tissue or the environment, since metabolism of the parent appears rapid [75].  The 
research conducted in this study included two organophosphate pesticides: Chlorpyrifos 
and Methyl Parathion.  
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Figure 2: Organophosphate Insecticides Versus Other Insecticides. This EPA graph 
indicates the application, in pounds, of organophosphates versus all other insecticides 
since 1980. Figure from the EPA [14]. The dotted line (at year 1990) signifies a change in 
the scale for time. 
 
2.6.1.1 Organophosphate Health Effects 
2.6.1.1.1 Acute 
 Effects following acute OP exposure are documented and well understood [30].  
The toxidrome commonly associated with acute OP overexposure is the inhibition of 
acetylcholinesterase (AChE) in the Central Nervous System (CNS) and the Peripheral 
Nervous System (PNS), as AChE is the primary target of OP pesticides [72, 76].  Once a 
dose of OP has been absorbed, it must undergo biotransformation to produce AChE-
inhibitory effects [13].  The majority of the biotransformation takes place in the liver via 
cytochrome P-450 (CYP) mediated oxidative desulfuration to remove the sulfur that is 
bound to the phosphorus, replacing it with an oxygen molecule [72].  This forms the 
reactive oxon form of the parent OP [72].  The oxon analog is responsible for AChE 
inhibition [77].   Hydrolysis and paroxonase (PON1) activity detoxify the oxon and 
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reduce it to byproducts [77].  OP can also bypass the desulfuration pathway and can be 
reduced by CYP-mediated dearylation into excretable metabolites without being 
transformed into the toxic intermediate [77]. 
 
 The nervous system is the target for OP AChE inhibition [77].  Acetylcholine is a 
neurohumoral transmitter that relays nerve impulses across synapses and neuroeffector 
junctions [73].  Hydrolysis of acetylcholine by AChE at cholinergic nerve terminals 
terminates the electrical conduction [72, 77].  The inhibition of AChE by the OP oxon 
results in accumulation of acetylcholine in the CNS and PNS and cholinergic synapses, 
resulting in the overstimulation of the muscarinic and nicotinic receptors [78].  
Overstimulation of these receptors can result in a cholinergic syndrome with symptom 
presentation based on the receptor type being targeted [76, 79].  
 
 Accumulation of acetylcholine in the CNS can result in confusion, hypothermia, 
tremors, paralysis and coma [76].  PNS muscarinic receptor depression can manifest as 
bradycardia, hypotension, miosis, gastrointestinal distress and lacrimation [76].  
Stimulation of nicotinic PNS receptors present as tachycardia, fasciculation, ataxia, 
convulsions, and paralysis [76].  Death from acute AChE inhibition is theorized to 
follow respiratory failure due to bronchoconstriction, increased bronchial secretions, 
intercostal and diaphragmatic muscle paralysis and inhibition of respiratory centers in 
the brain stem [13].  While AChE is the most understood cholinesterase when it comes 
to inhibition, a second type of cholinesterase, butylcholinesterase (also known as plasma 
pseudocholinesterase; BuChE), also undergoes inhibition, though its function is not well 
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understood [13].  It is believed that BuChE may be a sensitive biomarker of exposure 
when acute overexposure is suspected, but inhibition of BuChE alone cannot be 
considered a biomarker of effect when evaluating exposure to OP [13]. 
 
A second manifestation of acute OP excessive exposure is Intermediate Syndrome 
(IS).  This syndrome was first described in 1987 by Sri Lankan physicians observing 
hospitalizations of attempted suicide patients following ingestion of OP pesticides [13].  
Onset of this syndrome is anywhere from 24-96 hours following acute overexposure to 
OP [81].  The effects observed during this crisis do not appear to originate from AChE 
inhibition [77].  While the exact disease etiology is unknown, the symptoms are serious 
and include slowed respiration due to muscle weakness and weak neck muscles, in 
addition to proximal limb and cranial nerve palsies [13, 77].  IS could lead to death due 
to paralysis and respiratory failure [13]. 
 
A third sequela from excessive op exposure is Organophosphate-Induced Delayed 
Neuropathy (OPIDN) [13, 14, 82].  Also referred to as a neurotoxicity or a 
polyneuropathy in the literature, this syndrome manifests itself anywhere from 7-21 days 
following an acute cholinergic crisis (sources vary on the actual time for the signs to 
present) [14, 82].  Physiologically, sensory and motor axon degradation occurs in the 
distal regions of the peripheral nervous system and in the spinal cord [14].  A single 
exposure to an OPIDN-causing OP can lead to the inhibition of Neuropathy Target 
Enzyme (NTE) via phosphorylation [83].  Phosphorylation, along with ‘aging’ of at least 
70% of the NTE, is required for the signs of OPIDN to be observed [72].  Aging is a loss 
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of an alkyl group bound to NTE [80].  Studies have shown that inhibition of NTE is 
independent of AChE inhibition; however, age of the individual exposed does seem to 
be a factor on susceptibility, as young animals are at less of a risk to OPIDN following 
exposure due to the higher percentage of NTE inhibition required for young animals as 
compared to adult animals (90% versus 70%, respectively) [72].  Symptoms of this 
toxidrome include paresthesia, sensory loss, muscle weakness in extremities and limb 
muscles [84].  Not all OP pesticides are capable of causing OPIDN [14].  Only OP that 
are capable of aging NTE can cause OPIDN [13]. 
 
2.6.1.1.2 Chronic 
 While the effects from acute overexposures to OP pesticides have been well 
researched, there appears to be no consensus on the potential health effects from chronic, 
low-level exposures [72].  Recently, it has been proposed that chronic exposures to 
pesticides are contributing to neuropsychiatric disorders [85].  However, reviews of the 
research have found no conclusive evidence that low-level exposures to OP contribute to 
clinically significant neuropsychological effects or peripheral nerve dysfunction, though 
research in this area continues [72, 86-88].  Beyond neurological outcomes, public health 
concern has focused on the effects of pesticide exposures on the young.  The FQPA of 
1996 called for an evaluation of aggregate pesticide exposures on the general population, 
with special attention to infants and children [68].  With this increased focus on the 
young, new concerns arose questioning whether exposures to pesticides could result in 
teratogenic effects.  It has been observed that physiological differences in young animals 
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(low detoxication rate by CYP and PON1) may make them more sensitive to a 
cholinergic crisis than adult animals [77].  
 
 Epidemiological studies of OP suggest that exposure to the fetus during 
development may result in biochemical and behavioral abnormalities. These recent 
studies have begun to evaluate the association of exposures of pregnant mothers to 
pesticides and negative birth outcomes.  Outcomes evaluated in these studies include: 
decreased head circumference, decreased birth weight, decreased body length, decreased 
time of gestation, increased incidence of ADHD and memory impairment in children 
[77].  
 
2.6.1.2 Chlorpyrifos  
Chlorpyrifos (O,O-diethyl-O-(3,5,6-trichloro-2-pyridyl) phosphororthioate; CAS 
2921-88-2), a colorless to white solid organophosphate insecticide, has been used for the 
mitigation of cockroaches, termites, fleas and ticks [73, 77].  It is also used on vegetable, 
fruit, cotton, tobacco, corn crops and golf course turf to reduce damage from insects [77, 
89].  Chlorpyrifos for pesticide applications was first used in 1965 [77, 90].  While 
chlorpyrifos is still used in the control of pests in agricultural operations, its use in 
residential settings was phased out in 2001 [77].  The removal from residential settings 
was based on the findings of the EPA’s preliminary human health risk assessment [91].  
Current exposures to chlorpyrifos are primarily limited to agricultural settings [77].   
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2.6.1.2.1 Toxicokinetics 
2.6.1.2.1.1 Absorption 
 Chlorpyrifos is absorbed through ingestion, dermal and inhalation routes [74].  
Nolan et al. (1984) reported recovery of urinary biomarkers at 70% following an oral 
exposure to 0.5 mg/kg of chlorpyrifos and urinary biomarker recovery at 1.3% from a 
dermal exposure to 5.0 mg/kg from post-dosing samples [92].  A small amount is 
eliminated in the bile from phase II glutathione conjugations [77].  Timchalk et al. (2002) 
administered oral doses of 0.5-2.0 mg/kg to human volunteers [93].  Only 20-35% of the 
oral dose was recovered as 3,5,6-trichloro-2-pyridinol (a primary biomarker detected 
following exposure to chlorpyrifos; also known as 3,5,6-trichloropyridinol and TCPy) 
[93].  Chlorpyrifos exposures in the general population are thought to occur via ingestion 
of residues remaining on food products, though reductions of use in agriculture may 
reduce exposures from this route [51, 62, 77].  Dermal exposure to chlorpyrifos is not 
thought to be a major route of exposure in the general population following the restriction 
of its application, and inhalation exposures from agricultural applications are thought to 
be low, in relation to the diet [77].  While prior studies have suggested that concentration 
in ambient air and residues on surfaces may be a potential source of exposure for 
children, inhalation of ambient air in homes is no longer thought to be a source of 
exposure following the moratorium of chlorpyrifos use in residential scenarios [73].  
 
2.6.1.2.1.2 Distribution 
 Animal studies indicate that chlorpyrifos is distributed to all organs of the body 
following dosing [73].  Bioassay experiments suggest that chlorpyrifos is found in high 
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concentrations in adipose and fatty tissues [77].  Smith et al. (1967) suggested that the 
half-life in adipose tissue is 62 hours, while the half-life is reduced to 10-16 hours in the 
liver, kidney and the heart [94].  Abdel Rhaman et al. (2002) indicated that TCPy was 
observed in all tissues within 5 minutes following dosing with 14C radiolabeled 
chlorpyrifos (5mg/kg) [95]. 
 
2.6.1.2.1.3 Metabolism 
Chlorpyrifos is metabolized to form any of three final biomarkers: 3,5,6-
trichloropyridinol, diethylthiophosphate (DETP) or diethylphosphate (DEP) [77].  
Chlorpyrifos must be bioactivated/desulfurated and transformed into the chlorpyrifos-
oxon analog to inhibit AChE activity in the CNS and PNS [77].  The majority of the 
transformation occurs in the liver via cytochrome P-450 dependent monooxygenase 
desulfuration [72].  Detoxication of the oxon takes place through hydrolysis using 
paroxonase (PON1) as the catalyst to form DEP and TCPy [77].  Chlorpyrifos itself can 
be directly reduced to DETP and TCPy via cytochrome P-450-mediated dearylation [77].  
Animal studies have suggested that TCPy undergoes further metabolism through 
conjugation with glucuronic acid and sulfate [77].   
 
2.6.1.2.1.4 Elimination 
Half-life of elimination in humans has been estimated at 27 hours following an 
oral or dermal exposure [92].  Timchalk et al. (2007) recovered most of the administered 
dose in the urine 72 hours after dosing rats with ~50 mg/kg chlorpyrifos [96].  
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2.6.1.2.2 Mechanism of Toxicity 
Chlorpyrifos, by itself, is an inefficient inhibitor of AChE; however, the 
chlorpyrifos oxon, created by oxidative desulfuration, is an excellent inhibitor of the 
enzyme [77].  Metabolism of the parent and oxon metabolite is rapid, as can be seen in 
Figure 3. 
 
Figure 3: Chlorpyrifos Metabolism.  Chlorpyrifos can be either metabolized directly to 
TCP(y) and DETP or it can undergo further metabolism via Cytochrome P-450 to form 
chlorpyrifos oxon. The oxon analog is detoxified via Paroxonase 1 to form TCP(y) and 
DEP. Figure from ATSDR [73]. P-450= Cytochrome P-450; A-esterase= Paroxonase 1; 
TCP= 3,5,6- trichloropyridinol; DETP= diethylthiophosphate; DEP= diethylphosphate 
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2.6.1.2.3 Toxicity Assessment 
 The assessment for chlorpyrifos will be limited to select outcomes.  This 
assessment is focused on the more important public health risks.  Studies addressing 
human data are presented when available. 
 
2.6.1.2.3.1 Body Weight 
 Male and female rats with whole body exposure to 5,300 mg/m3 of a solution of 
Pyrenone Dursban for 4 hour lost a mean 10% body weight, however no weight 
variations were observed in rats dosed with 2,500 mg/m3 of Pyrenone Dursban 
pressurized spray [73].  Corley et al. (1989) dosed Fischer 344 rats with a maximum 
concentration of 287 µg/m3 for 6 hours a day, 5 days a week for 13 weeks [97].  No body 
weight differences were noted for any dosing group [97].  Rodents with acute oral 
exposure to chlorpyrifos at high doses have recorded decreases in mean body weight 
[73].  Moser (1995) orally dosed rats with a one-time 100 mg/kg of technical grade 
chlorpyrifos in corn oil had a 13.3% decrease in body weight 24 hours post dosing [98].  
No alterations in body weight have been observed from intermediate exposures in rodents 
[73].   
 
2.6.1.2.3.2 Neurological 
 Much of the literature pertaining to neurological effects following exposure to 
chlorpyrifos centers around the inhibition of cholinesterase activity.  An animal study by 
Breslin et al. (1996) evaluated pregnant Fischer 344 rats orally dosed with 15 mg/kg/day 
of technical grade Dursban F via gavage on gestation days 6-15 [99].  Erythrocyte AChE 
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activity was reduced ~80% as compared to controls [99].  An evaluation of OPIDN in 
hens by Capodicasa et al. (1991) resulted in maximum inhibition of NTE 5-7 days 
following a one time dosing of 60-150 mg/kg chlorpyrifos [100].  
 
 A study by Albers et al. (2004) evaluated the effects of chlorpyrifos on the central 
nervous system of occupationally exposed individuals [101].  The study evaluated 
employees at Dow Chemical Company where pesticides were manufactured. Cases and 
controls were identified from the facility.  A baseline examination was conducted as well 
as a follow-up examination approximately one year later.  Average creatinine-adjusted 
TCPy in the exposed group was 251 (µ)g/L (urine) and 192.2 µg/g (creatinine-adjusted) 
[101].  The study concluded that chronic, low-level occupational chlorpyrifos exposures 
were not associated with clinically evident or subclinical peripheral neuropathy when 
compared to controls [101]. 
 
Steenland et al. (2000) conducted a cross-sectional study with 191 termiticide 
applicators (both current and former) [102].  Recently exposed applicators had a mean 
urinary concentration of TCPy at 629.5 µg/L [102].  When the termiticide applicators 
were compared with a control group, few exposure-related effects were significant.  
Many were homogenous for effects on clinical examination.  However, significant 
differences were found when comparing the performance of the exposed on the length of 
sway and pegboard test to controls [102].   
 
 
 
 
25 
2.6.1.2.3.3 Developmental Effects 
 Deacon et al. (1980) evaluated physical abnormalities in a group of pregnant CF-1 
mice orally dosed with up to 25 mg/kg/day chlorpyrifos on gestation days 6-15; the study 
concluded that chlorpyrifos was not teratogenic [103].   
 
 Whyatt et al. (2004), along with Perera, used data obtained from the Columbia 
Center for Children’s Environmental Health in New York to determine the association of 
exposure of African American or Dominican pregnant women to pesticides [104].  
Women in this study participated in biomonitoring at the time of birth. Blood samples 
were collected from the umbilical cord at birth and from the mother within two days after 
giving birth [104].  Plasma TCPy levels were determined and a negative association was 
found between detection of TCPy and birth weight and length [104].  These data were 
further analyzed to determine the impact of chlorpyrifos exposure on neurodevelopment.  
Rauh et al. (2006) determined that “highly exposed” (chlorpyrifos >6.17 pg/g plasma) 
children 3 years of age scored lower on the Bayley Psychomotor Developmental Index 
and the Bayley Mental Development Index when compared to those exposed to a lower 
level (<6.17 pg/g) [105].  These levels are based on the chlorpyrifos detected in the 
umbilical cord plasma collected at the time of birth.  A follow-up study by Rauh et al. in 
2011 re-assessed these children at age 7 [106].  This study, using the original biomarker 
level at birth, reported that children exposed to chlorpyrifos in utero show deficits in the 
working memory index and the full scale IQ test [106].  
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 Eskenazi et al. (2004) investigated chlorpyrifos exposure and negative birth 
outcomes in the Center for the Health Assessment of Mothers and Children of Salinas 
Study (CHAMACOS) [107].  After sampling and analyzing maternal urine for 
chlorpyrifos biomarkers, no significant association was found between TCPy detection in 
urine and negative birth outcomes (birth weight, length, head circumference and length of 
gestation) [107].  
 
 Berkowitz et al. (2004) investigated the relationship between pesticide exposure 
and negative birth outcomes in the Children’s Environmental cohort study at Mount Sinai 
Hospital, New York [108].  Races were mixed in this study with approximately 50% of 
the participants identified as Hispanic [108].  Evaluation of urinary TCPy concentration 
was not found to have a significant association with reductions in birth weight and length; 
however, this study did find a slight decrease in head circumference when TCPy and 
PON1 activity were considered jointly [108].   
 
2.6.1.3 Methyl Parathion 
 Methyl parathion (O,O-dimethyl-O-(p-nitrophenyl)-phosphororthioate; CAS 298-
00-0), first manufactured in the USA in 1954, is an insecticide used on crops, such as 
cotton and soybeans [74, 109].  It is a white crystalline solid or brownish liquid 
containing 80% methyl parathion as the active ingredient [74, 109].  Exposures to the 
general population are thought to be low [74].  Inhalation exposures are thought to be the 
route of exposure to individuals living near agricultural application of methyl parathion 
(MP) [74].  Dermal may be the most relevant exposure route based on the fact that the 
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EPA has accepted voluntary cancelation of the use of MP on a variety of food products 
and residential application is prohibited [74, 110].  The EPA determined that MP posed 
an unacceptable dietary risk to children aged 1-6 [110]. 
 
2.6.1.3.1 Toxicokinetics  
2.6.1.3.1.1 Absorption 
 Humans appear to readily absorb MP via ingestion, inhalation and dermal 
exposures [74].  Oral absorption is limited by first pass metabolism in the small intestine 
[109].  Human exposures to methyl parathion have shown that AChE inhibition takes 
place following dermal absorption [74].  The ATSDR indicated that exposure can occur 
through inhalation, though no human studies identified absorption via inhalation [74].   
 
2.6.1.3.1.2 Distribution 
 Distribution studies involving human exposures are limited.  A human dosing 
study by Morgan et al. (1977) indicated that ingestion of either 2 mg or 4 mg of MP in 
food resulted in urinary excretion of biomarkers, with the highest concentrations 4 and 8 
hours after ingestion [111].  Garcia-Repetto et al. (1997) reported that MP distributed to 
various body compartments of the rat following gavage and results indicated that, 
depending on the tissue, the half-life of elimination is anywhere from 8 to 16 days [112].  
Bioassay studies have suggested that MP distributed to the blood, brain, liver and adipose 
tissue [109].   
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2.6.1.3.1.3 Metabolism 
 Like other OP pesticides, MP can be either detoxified or bioactivated after 
absorption.  Detoxication takes place via dearylation by oxidatively cleaving the 
compound to form paranitrophenol (PNP) and dimethyl thiophosphate [109].  Oxidative 
desulfuration via Cytochrome P-450 transforms MP to the more toxic analog, Methyl 
Paraoxon [109].  The oxon is detoxified by paraoxonase (PON1) to form either 
paranitrophenol or dimethylphosphate and can be further reduced to form conjugates with 
glucuronic acid and sulfate [74, 109].  Methyl parathion itself is not effective at inhibiting 
AChE [74].  Studies have indicated that oral absorption of MP limits its toxicity due to 
first pass metabolism [74].  
 
2.6.1.3.1.4 Elimination 
 Abu-Qare et al. (2000) used pregnant rats to apply a dermal dose of a radiolabeled 
MP solution. Urinary recovery of was 91% within 96 hours [113].  Excretion from an 
oral exposure occurs mainly through urine and appears to be rapid.  A human volunteer 
study by Morgan et al. (1977) suggested that 86% of 4-nitrophenol had been eliminated 8 
hours following dosing, with the highest recovery during the first 4 hours [111]. 
 
2.6.1.3.2 Mechanism of Toxicity 
 Like other organophosphate pesticides, MP must be bioactivated to form methyl 
paraoxon in order to elicit AChE inhibitory effects, as seen in Figure 4 [112].  
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Figure 4: Methyl Parathion Metabolism.  Methyl Parathion can be reduced directly to 
form PNP and DMTP or it can undergo activation via cytochrome P-450 to form methyl 
paraoxon.  The oxon analog is detoxified via PON1 to form PNP and DMP. Figure from 
Panuwet et al. (2009) [114]. DMTP= dimethyl thiophosphate; DMP= dimethylphosphate. 
Reprinted with permission. 
 
 
2.6.1.3.3 Toxicity Assessment 
 The assessment for methyl parathion will be limited to select outcomes.  This 
assessment focuses on relevant public health outcomes.  Studies addressing human data 
are presented when available. 
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2.6.1.3.3.1 Body Weight 
 Studies have evaluated variations in body weight following acute, intermediate 
and chronic oral exposures.  Tian et al. (1997) did not observe any significant body 
weight variations in mice dosed with 5 mg/kg/day for 15 days [115].  Two of eight dogs 
dosed with 3.0 mg/kg/day for 13 weeks were reported to be emaciated and dehydrated; 
these effects were not noted in dogs dosed with concentrations that were orders of 
magnitude lower [74].  Rats orally dosed with methyl parathion at concentrations of 2.5 
mg/kg/day for 2 years showed significant reductions in body weight in comparison to 
controls [74].  However, this variation was not consistent during the study duration and 
variations were not observed in animals dosed with concentrations that were orders of 
magnitude lower [74].  
 
2.6.1.3.3.2 Neurological 
 The neurotoxic effects of MP center around the inhibition of AChE [112].  
Rodnitzky et al. (1978) orally dosed two male volunteers with 2 mg/day of MP for 5 
days, and, 8 weeks later, were orally exposed to 4 mg/day of MP for 5 days.  No 
significant reductions in AChE-activity were observed for either dosing [116].  Male rats 
orally dosed with 5 mg/kg via gavage displayed cholinergic signs seven minutes post 
dosing, resulting in an approximately 44% reduction in plasma cholinesterase when 
compared to controls [74].  Crittenden et al. (1998) dosed mice with MP at 1, 3 and 6 
mg/kg/day recorded decreased brain AChE activity at various points over the 28-day 
study in the groups dosed with 3 mg/kg and 6 mg/kg [117]. 
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 In the 1990’s, MP was illegally applied in residences in at least nine Midwestern 
and Southern states [118].  The target population of one of the studies investigating MP 
exposure was children who were 6 years of age or younger at the time of MP application.  
Exposure was established based on either wipe samples from the home (in Ohio and 
Mississippi) or the detection of paranitrophenol (PNP) in a urine sample (Ohio only).  
The study evaluated whether exposed children had an adverse neurological outcome.  
Based on the results of tests used to evaluate neurobehavior and general intelligence, the 
exposures were not associated with negative outcomes on most neurobehavioral tests 
[118].  The findings do suggest that those children exposed may have alterations in short-
term memory, but the authors note that the findings are not conclusive because the effects 
are not consistent across both study sites [118].  The delay in time between the 
application of MP and neurobehavioral testing (2.5 years in Mississippi and 4.5 years in 
Ohio) and the age of the children at the time of the neurobehavioral assessment may have 
affected the findings [118].  
 
2.6.1.3.3.3 Developmental Effects 
 Numerous studies have used rodents to identify the effects of methyl parathion on 
pregnant dams during gestation.  A mouse study by Gupta et al. (1985) identified 
increased observed visible signs of toxicity in dams and fetuses exposed to 1.5 mg/kg/day 
of MP [119].   
 
The Eskenazi et al. (2004) study referenced in the chlorpyrifos section (Page 26) 
also evaluated the association of urinary concentrations of PNP to negative birth 
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outcomes [107].  When comparing women with detects of the biomarker to those that did 
not have a detect for PNP, women with levels of PNP above the median 
(median=0.05µg/L) had children with increased head circumference when compared with 
women without a detect (β =0.29cm, p=0.06) [108].  Additionally women with PNP 
levels below the median had children with increased length as compared to women with 
no detects (β=0.60 cm; p=0.03) [107]. 
 
2.6.2 Pyrethroids 
Pyrethrum, a natural extract used as an insecticide, is obtained from the 
chrysanthemum cinerariaefolium and chrysanthemum cineum flowers [120].  Use of 
these extracts for insect mitigation can be traced back at least 2,000 years to China and 
Persia [13, 121].  While effective at controlling insects, degradation of pyrethrum occurs 
quickly in sunlight and the environment [120].  Pyrethroids are synthetic analogs of 
pyrethrums [13, 120].  The synthetic pyrethroids are similar in structure to pyrethrum but 
are more resistant to rapid degradation [120].  
 
Pyrethroids are insecticides used in agricultural settings and household 
applications for the control of scabies, lice and mosquitoes and, in addition, are among 
the most frequently used pesticides [13, 122].  Pyrethrum, as a group, contains six active 
compounds referred to as pyrethrins [123].  In comparison, there are over 1,000 synthetic 
pyrethroids, though only a few of those are commonly used in the US [120].  Several 
examples of these compounds can be seen in Table 5.  The mechanism of action for 
pyrethroids is similar for insects and mammals; however, because of a faster metabolism 
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and lower sensitivity at the target site, mammals are relatively resistant to the actions of 
pyrethroids [121].  
 
Pyrethroids are classified as either Type I or Type II, depending on their physical 
properties and toxicological outcomes in rats, though other rodents have also been used to 
classify the effects of an overexposure [64, 124].  Type I compounds elicit aggressive 
behavior, increased sensitivity to external stimulation, startle response, fine and whole 
body tremors as well as prostration in rats [124].  These sequalae are referred to as T-
syndrome [124].  Type II pyrethroids are characterized by burrowing, salivation, coarse 
tremors, choreoatetosis and clonic seizures in rats [124].  In addition, Type II pyrethroids 
are chemically differentiated from Type I compounds by the presence of a cyano (CN) 
group on the alpha carbon [124].  Outcomes from exposure to Type II compounds are 
referred to as CS-syndrome [124].  Pyrethroids contain two chiral carbons and, in some 
cases, an additional carbon on the alcohol moiety to total three [13, 120].  In addition to 
existing in cis- and trans- conformations, pyrethroids can result in up to eight different 
isomers [13, 120].  The conformation of the compound can have an effect on toxicity 
[13].  
 
Table 5: Partial List of Pyrethrins and Pyrethroids. 
 
Pyrethrins Type I Pyrethroids Type II Pyrethroids 
Pyrethrin I Allethrin Cyfluthrin 
Pyrethrin II Bifenthrin Cyhalothrin 
Cinerin I Permethrin Deltamethrin 
Cinerin II Resmethrin Fenvalerate 
Jasmolin I Tefluthrin Flumetrhin 
Jasmolin II Tetramethrin Tralomethrin 
Adapted from ATSDR Toxicological Profile [120]. 
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 Pyrethrins and pyrethroids are degraded by sunlight and typically do not persist in 
the environment, though permethrin and cyhalothrin persist longer due to structural 
characteristics [120].  Environmental half-life ranges from days to a few weeks [120].  
The compounds are typically immobile in soil and are biodegradable in the environment, 
though it has been shown that this insecticide does bioaccumulate in aquatic organisms 
[120].  Permethrin is the most frequently used pyrethroid in the US and is the pyrethroid 
that will be focused on in this study [64, 120].   
 
2.6.2.1 Health Effects 
2.6.2.1.1 Acute 
While their use as an insecticide is effective and potent, they pose little hazard to 
humans due to their low mammalian toxicity (three orders of magnitude lower than that 
of insects) [125].  The adverse health effect of pyrethroids depends on their classification, 
though their primary target is disruption of the voltage-gated sodium channels of the 
nervous system [121, 24, 126].  Type I pyrethroids function by prolonging the opening of 
the sodium ion channel to cause repetitive firing of the action potential [13].  Type II 
compounds also work on the sodium channel; however, instead of rapid fire, the sodium 
channel remains open which results in depolarization of the channel and does not allow 
for the generation of an action potential [13].  
 
2.6.2.1.2 Chronic 
 The reported effects of chronic, low-level exposure to pyrethroids, if any, are 
limited in the literature.  However, because of the rapid metabolism of the compounds, 
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pyrethroids are not believed to result in neurological signs from chronic, low-level 
exposures [120].  In 1999, the Cancer Assessment Review Committee (EPA) classified 
pyrethrins as “likely to be a human carcinogen by the oral route” based on a study 
finding increases in thyroid follicular cell tumors in male rats and increased incidence of 
hepatocellular adenomas and carcinomas in female rats fed high doses of pyrethroids 
(1,000 ppm and 3,000 ppm) [120].  However, other animal studies using high dosings 
have not come to the same conclusions [120].  There has also been an attempt to correlate 
pyrethroids exposure to reduction in semen and hormone levels in adult men [65, 127].  
 
2.6.2.2 Toxicokinetics 
2.6.2.2.1 Absorption 
 Studies have indicated that pyrethroids are readily absorbed through inhalation 
exposure and moderately through oral exposure, while less than 2% of the applied dose 
following dermal exposure is absorbed [120, 128].  Oral absorption takes place in the 
intestinal tract, though first pass metabolism may underestimate the true absorbed dose 
[120].  An inhalation study in humans by Leng et al. (1997) indicated that urinary 
biomarkers were 93% recovered within 24 hours, with peak rates between 30 minutes and 
3 hours, indicating rapid metabolism [129].  Human and animal information on dermal 
absorption is limited [120].  In occupational settings, exposures to pyrethroids are thought 
to occur from inhalation and dermal exposure, though studies have indicated that the skin 
is an effective barrier to absorption [120].  General population exposure is suggested to 
be through the ingestion of agricultural products that have been treated with pyrethroids 
[120, 125].  It is suggested that general population exposure also originates from 
 
 
36 
household treatments with pyrethroids [128].  Because of their lower vapor pressure, 
pyrethroids can form particulates at room temperature and partition into household dusts 
[128].  Because young children tend to have higher hand-to-mouth activity, this may also 
be a relevant source of exposure [130].  
 
2.6.2.2.2 Distribution 
In humans, once absorbed into the blood stream, pyrethroids are rapidly 
distributed [128].  Pyrethroids are theorized to distribute to most tissues, especially those 
high in lipid content [120].  They are also thought to concentrate in the central and 
peripheral nervous systems [120].  Distribution studies for dermal and inhalation 
exposures in humans and animals was lacking. 
 
2.6.2.2.3 Metabolism 
 Many of the studies on the metabolism of pyrethroids are based on mammalian 
animal models [120].  The parent compound of pyrethroids is the active, toxic form, as 
metabolism forms byproducts that are thought to have little or no toxicity [13, 120].  
Metabolism occurs through two major pathways: hydrolysis of the ester bond and 
oxidation of the alcohol moiety [13].  One pathway may be the major path of 
biotransformation, depending on the type of pyrethroids encountered [120].  The 
biomarker 3-Phenoxybenzoic Acid (3-PBA) will be evaluated in this research.  It is a 
biomarker for 10 out of the 18 common pyrethroids registered in the US [128].  
 
 
 
 
37 
2.6.2.2.4 Elimination 
 Depending on the specific pyrethroid encountered and the rate of exposure, 
elimination half-life ranges from 6.4-16.5 hours [128].  Animal studies indicate that Type 
I and II pyrethroids are eliminated within 4-12 days following oral dosing and the 
majority is eliminated within 12-48 hours [120]. 
 
2.6.2.3 Mechanism of Toxicity 
 The parent form of the pyrethroid is responsible for interruption in the sodium 
channel action potential.  Metabolism detoxifies the parent pyrethroid, inactivating the 
Type I and II effects, and forms excretable metabolites, as can be seen in Figure 5. 
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Figure 5: Permethrin Metabolism.  Permethrin undergoes detoxication to form 3-
Phenoxybenzoic Acid, the metabolite of interest in this research. Figure from Hardt et al. 
(2003) [131].  Cis/Trans-Cl2CA= 2,2- Dimethylcyclopropane Carboxlic Acid; 3-PBA= 3-
Phenoxybenzoic Acid. Reprinted with permission. 
 
2.6.3.3 Toxicity Assessment 
Because there are a variety of synthetic mixtures and conformations of 
pyrethroids available, the information in this section will not be limited to one specific 
pyrethrin or pyrethroid.  This assessment is limited to relevant public health risks.  
 
2.6.3.3.1 Body Weight 
 Various animal studies evaluated and associated pyrethroid and pyrethrin 
exposure to reductions in body weight and food consumption.  Parker et al. (1984) orally 
dosed female dogs with fenvalerate at 1,000 ppm in the diet for 6 months; dosed dogs had 
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significant decreased body weight and food consumption when compared to controls 
[132]. 
 
2.6.3.3.2 Neurological 
 In occupational exposure scenarios, paresthesia is reported following dermal 
contact to pyrethroids [121].  Other acute signs include muscular fasciculations, headache 
and convulsions [120].  Signs of neurotoxicity seem to dependent on whether the 
exposure was to Type I or Type II pyrethroids.  Neurological signs in laboratory animals 
from an exposure include aggressive behavior, increased sensitivity to external 
stimulation, startle response, tremors and prostration for Type I compounds and 
burrowing, salivation, coarse tremors, choreoatetosis and clonic seizures for Type II 
compounds [124].  Oral dosing with permethrin in rats resulted in a significant decrease 
in motor activity at 200 mg/kg [133].  Hypersensitivity to sound has been reported in 
other bioassay experiments [120].  
 
2.6.3.3.3 Developmental Effects 
 Pregnant rats exposed to a maximum of 600 mg/kg/day of total pyrethrins 
(extract) on gestation days 6-15 did not result in developmental toxicity, though maternal 
toxicity was observed in rats dosed with 75 mg/kg/day [134].  The type of pyrethroids 
may have an effect on the toxicity outcomes following oral exposure.  Pregnant dams 
dosed with a maximum of 8 mg/kg/day of cypermethrin on gestation days 6-15 did not 
have any significant differences between control animals [135].  
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 Berkowitz et al. (2004) evaluated the association of phenoxybenzoic acid in urine 
and decreases in birth weight, length and head circumference in the Mount Sinai study 
(referenced on page 26).  No significant associations were found between the exposure 
and birth outcomes [108]. 
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Chapter 3 
Methods 
3.1 Data Source 
 The data evaluated in this research originated from the 2001-2002 NHANES 
sampling event.  National health monitoring dates back to the National Health Survey Act 
of 1956 that gave authorization for the creation of a continuing survey that would give 
statistical data on the amount, distribution and types of illness and disability in the US 
[136].  The National Health Examination Survey’s of the 1960’s (NHES I-III) were 
multi-year studies that evaluated either select chronic diseases, or growth and 
development, in a variety of age groups [136].  The impact of nutrition and its 
relationship to health status was added to the study design in the 1970, thus creating the 
National Health and Nutrition Examination Survey and resulted in multi-year studies 
(NHANES I-III and HHANES), with a different focus for each study event [136].  
Beginning in 1999, NHANES became a continuous, annual survey event in the US [136].  
 
 Sampling for the 2001-2002 NHANES collected data from 11,039 participants 
aged 6-85+ in 30 Primary Sampling Units (PSU) across the US.  A PSU is defined as a 
county or a group of contiguous counties [137].  The PSU can be further divided into 
blocks or groups of blocks within one of those counties and households on the blocks.  
The PSUs were visited over a 12-month period [137].  Examinations, interviews and 
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specimen collections took place at Mobile Examination Centers (MEC) set-up in the PSU 
for easy data collection [137].  The Centers for Disease Control and Prevention (CDC) 
does not supply specific information on the locations of PSU in order to protect the 
confidentiality of participants [138].  Demographic information gathered from the 
examination was entered into a database file by NHANES researchers.  The information 
found in this file included participant’s age, gender, ethnicity, education level, marital 
status and household income.  This information was imported into a Microsoft Access 
(2003) database for matching to other data files from the NHANES database. 
 
 Priority non-persistent pesticides and their biomarkers as well as organophosphate 
pesticide data were supplied in a separate data file within the 2001-2002 NHANES 
Laboratory subsection of the NHANES website.  This dataset included information from 
a subset of 3,152 individuals from the main sampling event and included information for 
18 biomarkers.  Analysis of spot urine (random) samples to evaluate for the presence of 
pesticide biomarkers was conducted for a randomly selected sample from the overall 
NHANES sample population [139]. 
 
After collection of the samples at each MEC, specimens were shipped to the 
Division of Environmental Health Laboratory Sciences for analysis using the appropriate 
shipping and storage methods [139].  The urinary levels of the biomarkers were measured 
using one of two mass spectrometric methods [139].  Detailed laboratory analytical 
information is available in the NHANES pesticide documentation and NHANES 
laboratory procedures manual.  For each specific biomarker, the dataset indicated 
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whether or not the biomarker was detected and, if detected, the urinary level in 
micrograms/liter (µg/L).  If the biomarker was not detected in the sample, a value of the 
detection limit (DL) divided by the square root of two (DL/√2) was reported [139].  Also 
included in this data file was the urinary concentration of creatinine in the sampled 
individual, reported in mg/dL.  Information from this subset was matched using a 
common numerical identifier to the information in the demographic data file.  This allows 
all samples collected from one individual to be matched across multiple, individual data 
files.  
 
3.2 Data Analysis 
 The pesticide subfile was imported into SAS (Version 9.2) to undergo basic 
statistical analysis.  The frequency of detection was determined for each biomarker in the 
pesticide dataset.  Biomarkers selected for inclusion in this research were those that were 
detected in more than 50% of the samples.  This criterion has been used in other 
population biomarker analysis [140].  Three biomarkers met the requirement for inclusion 
in this research: 3,5,6-trichloropyridinol, paranitrophenol and 3-phenoxybenzoic acid.  
The analysis was limited to biomarkers that could be related to a parent compound.  The 
non-specific biomarkers for OP compounds were not analyzed in this study.  
 
 After using Access to match the pesticide biomarker concentrations to 
demographic information (age, ethnicity, and gender) from NHANES using a common 
identifier, data was stratified into individual Access queries for each biomarker.  The 
queries also contained information on each child’s and adolescent’s height (in 
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centimeters, cm) and weight (in kilograms, kg) that were also matched in the Access 
database using the NHANES common identifier.  Biomarkers of clinical chemistry 
(biochemical concentrations) were related to individuals included in the pesticide data 
file.  From the Access database, individual files were created in Microsoft Excel (2003) 
for import into SAS for analysis.  The creation of Excel files also allowed for the data to 
be examined.  There were numerous instances where values were missing across all of 
the NHANES databases used in this research.  The number of missing individual values 
is observable when examining the number of individuals involved in each analysis across 
the data. 
 
Results for biomarker concentrations were log-transformed to determine the 
geometric mean.  This transformation corrects for the non-normal distribution found in 
the sample due to the large amount of concentrations below or close to the Limit of 
Detection (LOD) [141-142].  The overall geometric and arithmetic means for each 
biomarker were determined and the confidence intervals and quartiles were calculated.  
The geometric mean for each participant that had a detectable level of the biomarker in 
their urine was also calculated.  Once the data was imported into SAS, a Students t-test 
was performed and the geometric mean determined for overall biomarker concentrations 
and for the gender subgroup.  An Analysis of Variance (ANOVA) was performed and the 
geometric mean was determined for the age and ethnicity subfiles for each biomarker; the 
Tukey post-hoc analysis was used to determine which means were significantly different.  
To account for dilution of urine in the sample, the creatinine-adjusted geometric mean 
values (in microgram/g creatinine, µg/g) were determined and supplied along side the 
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biomarker concentration (µg/L) for comparison. Additionally, the correlation of 
biomarker detects was conducted using Systat 13 in an attempt to determine if the 
exposures were associated with each other across the overall exposure group.  Level of 
significance was reported based on the variance findings from the SAS analysis (either 
pooled or satterthwaite).  
 
 Logistic regression was performed on the data from the pesticide subsample.  This 
regression used multiple independent variables to model the relationship between the 
predictive independent variables and the dichotomous, dependent outcome (a yes or no 
detection of the biomarker in the urine sample).  Logistic regression predicted the change 
in the coefficient (β) in relation to a change in the reference group based on the 
independent variables in the model: gender (dichotomous data), age (continuous data) 
and ethnicity (categorical data).  The group with the largest amount of individuals was 
used as the reference group for gender and ethnicity.  In these regression models, females 
and Non-Hispanic Whites were the largest groups. Additionally, the model supplied odds 
ratios to indicate which independent variable had a higher odds of having a detect for the 
biomarker in the urine sample in relation to the reference group.  
 
A Students t-test was conducted and the arithmetic mean was determined for the 
height and weight of each of the biomarker detect and non-detect groups for children 
aged 6-11.  This analysis determined if children with a recorded detect had a statistically 
significant difference in either height or weight when compared to those children that did 
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not have a recorded exposure to the biomarker.  Level of significance was reported based 
on the variance findings from the SAS analysis (either pooled or satterthwaite). 
 
An additional data file supplied by the NHANES contained biochemical 
concentrations for participants aged 12-85+.  Included in this file were the concentrations 
of liver and kidney enzymes, as well as electrolyte concentrations, among others.  The 
biochemical concentrations were imported into an Access database.  This information 
was used to create Excel files for overall male and female concentrations and overall 
participant concentrations.  Student’s t-tests were conducted on each break-down group 
and the arithmetic means were determined.  These divisions would determine if age or 
gender differences show variations in the comparison of individuals that had a coded 
detect for the biomarker versus those with a non-detect.  As with the other analyses, the 
level of significance was reported based on the variance findings from the SAS analysis 
(either pooled or satterthwaite). 
 
The NHANES demographic database file, as well as the pesticide subsample file, 
contained values for interview weight, MEC exam weight and a value for masked-
variance pseudo-PSU [137].  These values were not incorporated into this data analysis.  
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Chapter 4 
Results 
 Results are grouped by pesticide and biomarker.  Analysis for each biomarker was 
conducted to determine: 
1. The overall and creatinine-adjusted geometric and arithmetic mean for all 
individuals in the sample. 
2. Geometric mean for individuals coded as a detect for the biomarker. 
3. Geometric mean comparison for males versus females. 
4. Geometric mean comparison between ethnic groups. 
5. Geometric mean comparisons for age groupings. 
6. Height and weight comparisons for children based on detects versus non-detects. 
7. Biochemical arithmetic mean comparisons for males, females and the biomarker 
overall. 
8. Logistic regression comparison for all groups involved in the research. 
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4.1 Overall Detection Frequency 
TCPy and 3-PBA were detected in more than 75% of the sample.  PNP met 
inclusion criteria by a small margin (53%).  The remaining specific biomarkers were 
detected in much lower amounts in the sample.  
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Figure 6: Detection Frequency of Urinary Pesticide Biomarkers.  Detection frequencies 
for specific pesticide biomarkers can be viewed in Table 6. 
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Detection of Biomarkers Among Individuals
0
500
1000
1500
2000
2500
3000
3500
3,5,6-
Trichloropyridinol
Paranitrophenol 3-Phenoxybenzoic
Acid
N
u
m
b
er
 o
f 
In
d
iv
id
u
al
Missing Values
Non-Detects
Detects
 
 
Figure 7: Number of Detections Among Individuals. 
 
Table 6: Detections Among Individuals in the Dataset. 
 
 Detects 
Non-
Detects 
Missing 
Values 
Total 
Analyzed 
Detection 
Frequency 
3,5,6-Trichloropyridinol 2368 643 141 3011 78.6% 
Paranitrophenol 1580 1395 177 2975 53.1% 
3-Phenoxybenzoic Acid 2395 689 104 3048 77.4% 
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4.2 Correlation of Exposures 
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Figure 8: Detection Frequency of Biomarkers Among Individuals.  
 
 
Table 7: Evaluation of Multiple Exposures Among Individuals in the Sample. 
 
 
No 
Detects 
One 
Detect 
Two 
Detects 
Three 
Detects Total 
Number of Individuals 1205 1030 536 204 2975 
Percentage of Individuals 40.50% 34.60% 18% 6.90% 100% 
 
When evaluating individuals with detectable levels of the biomarker in their urine, 536 
individuals had recorded detects for two biomarkers, while only 204 individuals were 
exposed to all three biomarkers.  
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Figure 9: Pearson Correlation of Log-Transformed Biomarker Concentrations in Urine. 
 
Table 8: Pearson Correlation Matrix. 
 
  TCP_LOG PNP_LOG PBA_LOG 
TCP_LOG 1     
PNP_LOG r =0.357 1   
PBA_LOG r= 0.267 r= 0.28 1 
All values listed in Table 8 reflect the linear correlation between the biomarkers (r), as 
seen in Figure 9. 
 
Table 9: Spearman Correlation Matrix. 
 
  TCP_LOG PNP_LOG PBA_LOG 
TCP_LOG 1     
PNP_LOG rs= 0.37 1   
PBA_LOG rs= 0.299 rs= 0.291 1 
This correlation examines the nonparametric correlation between the biomarkers (rs). 
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Correlation analysis conducted on the log transformed data does not indicate that 
the levels are highly correlated.  Both the Spearman and Pearson correlation was 
conducted to determine if the results varied.  The results appear to be relatively close.   
 
4.3 Organophosphate 
4.3.1 Chlorpyrifos Biomarker: 3,5,6-Trichloropyridinol (TCPy) 
4.3.1.1 Descriptive Statistics 
The information covered in the following figures and tables characterizes the 
exposures to chlorpyrifos in the overall sample and in various subgroups. 
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Figure 10: Comparison of Means for 3,5,6-Trichloropyridinol. µg/l= Micrograms per 
Liter; µg/g= Micrograms per Gram. Adjusting for creatinine results in means (both 
geometric and arithmetic) that are lower than if using the concentration of the TCPy 
biomarker in urine (µg/L) alone.  Limit of Detection (LOD) for TCPy in sample was 0.4 
µg/L. 
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Table 10: Descriptive Statistics for 3,5,6-Trichloropyridinol. 
 
 Biomarker (µg/L)a    Creatinine Adjusted (µg/g)b  
 
Geometric 
 Mean 
Arithmetic  
Mean   
Geometric 
 Mean 
Arithmetic 
 Mean 
nc 3011 3011  n 3009 3009 
Mean 2.07 4.28  Mean 1.98 3.42 
LCLd 1.98 4.06  LCL 1.91 3.25 
UCLe 2.17 4.50  UCL 2.06 3.58 
SDf 3.69 6.06  SD 2.98 4.75 
P25g 0.77 0.77  P25 1.08 1.08 
P50h 2.61 2.61  P50 2.23 2.23 
P75i 5.33 5.33  P75 4.08 4.08 
P90j 9.34 9.34  P90 6.89 6.89 
P95k 13.87 13.87  P95 10.27 10.27 
Minl 0.28 0.28  Min 0.0362 0.0362 
Maxm 79.59 79.59  Max 97.29 97.29 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(n) = Number in 
Sample; d(LCL) = Lower Confidence Limit; e(UCL) = Upper Confidence Limit; f(SD) = 
Standard Deviation; g(P25) = Lower Quartile; h(P50) = Median; i(P75) = Upper Quartile; 
j(P90) = 90th Percentile; k(P95) =95th Percentile; l(Min) = Minimum m(Max) = Maximum 
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Geometric Mean for Detects of 3,5,6-Trichloropyridinol
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Figure 11: Comparison of Detectable Geometric Mean Concentrations for                      
3,5,6-Trichloropyridinol.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
 
 
Table 11: Descriptive Statistics for Detectable Levels of 3,5,6-Trichloropyridinol. 
 
  GMc LCLd UCLe SDf Median ng 
Biomarker (µg/L)a 3.56 3.44 3.69 2.43 3.68 2368 
Creatinine Adjusted (µg/g)b 2.91 2.82 3.01 2.23 2.87 2366 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(GM) = Geometric 
Mean; d(LCL) = Lower Confidence Limit; e(UCL) = Upper Confidence Limit; f(SD) = 
Standard Deviation; g(n) = Number in Sample 
 
 
The geometric mean was determined for 78.6% of the individuals that had a 
detectable level of biomarker in their urine sample.  Based on this analysis, the geometric 
mean for only detectable levels of the biomarker was 1.49 µg/L higher that the overall 
geometric mean.  
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4.3.1.2 Comparative Statistics 
 
Male and Female Geometric Mean for 3,5,6-Trichloropyridinol
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Figure 12: Comparison of Geometric Mean Values of Males Versus Females for         
3,5,6-Trichloropyridinol.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram.  
Color-coded “*” indicates males are significantly different from females. 
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Table 12: Student’s t-test Comparing Geometric Means of Males Versus Females for 
3,5,6-Trichloropyridinol. 
 
Biomarker (µg/L)a        
  GMb LCLc UCLd SDe Median nf (D/ND)g Ph 
Male 2.45 2.29 2.61 3.56 3.05 1416 (1180/236) 
<0.0001 
 Female 1.78 1.67 1.90 3.75 2.27 1595 (1188/407) 
Total      3011 
        
Creatinine Adjusted (µg/g)i        
  GM LCL UCL SD Median n p 
Male 1.98 1.87 2.10 2.97 2.20 1416 0.9423 
 Female 1.99 1.88 2.10 2.99 2.27 1593 Total      3009 
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram 
 
Males have a statistically significant higher geometric mean (GM) when 
compared to females, but only when using the unadjusted biomarker concentration in 
urine (µg/L).  Adjusting for creatinine negates any significant difference.  
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Ethnicity Geometric Mean Concentrations for 3,5,6-Trichloropyridinol
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Figure 13: Comparison of Geometric Mean Values of Ethnic Groups for                         
3,5,6-Trichloropyridinol.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
Color-coded “****” indicates this groups is significantly different from all other groups.  
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Table 13: One-Way ANOVA and Tukey Analysis Comparing Geometric Means of 
Ethnic Groups for 3,5,6-Trichloropyridinol. 
 
Biomarker (µg/L)a       
 GMb LCLc UCLd SDe nf (D/ND) g Ph 
Mexican American 2.12 1.88 2.37 3.36 744 (611/133) 
<0.0001 
 
Non-Hispanic Black *all 2.60 2.35 2.85 3.52 762 (635/127) 
Non-Hispanic White 1.84 1.62 2.05 3.88 1255 (936/319) 
Other Hispanic 1.77 1.09 2.45 3.96 129 (94/35) 
Other 1.70 0.99 2.41 3.97 121 (92/29) 
Total     3011 
       
Creatinine Adjusted (µg/g)i       
 GM LCL UCL SD n p 
Mexican American 2.10 1.91 2.30 2.74 744 
0.1847 
 
Non-Hispanic Black 1.94 1.73 2.15 2.94 761 
Non-Hispanic White 1.99 1.82 2.16 3.10 1254 
Other Hispanic 1.66 1.09 2.23 3.30 129 
Other 1.86 1.32 2.41 3.06 121 
Total     3009 
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects;  h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram. *all 
indicates that this group is significantly different than all other ethnic groups. 
 
The unadjusted biomarker concentration in urine (µg/L) for non-Hispanic Blacks 
had a significantly elevated GM as compared with the other ethic groups.  However, 
when adjusting for creatinine, there were no significant findings. 
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Ethnicity Geometric Mean Concentrations for 3,5,6-Trichloropyridinol
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Figure 14: Comparison of Geometric Mean Values of Age Groups for                         
3,5,6-Trichloropyridinol.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
Color-coded “****” indicates which groups are significantly different from each other. 
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Table 14: One-Way ANOVA and Tukey Analysis Comparing Geometric Means of   
Age Groups for 3,5,6-Trichloropyridinol. 
 
  Biomarker (µg/L)a       
  GMb LCLc UCLd SDe nf (D/ND)g Ph 
Children* 2.72 2.44 2.99 3.39 573 (491/82) 
<0.0001 
 
Adolescent* 2.84 2.59 3.08 3.38 741 (643/98) 
Adult** 1.65 1.47 1.83 3.77 1697 (1234/463) 
Total     3011 
       
Creatinine Adjusted (µg/g)i       
  GM LCL UCL SD n p 
Children*** 3.26 3.03 3.49 2.78 573 
<0.0001 
 
Adolescent*** 2.09 1.90 2.28 2.66 740 
Adult*** 1.76 1.61 1.90 3.02 1696 
Total     3009 
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram.     
* Indicates group is significantly different from Adults.                                                     
** Indicates that group is significantly different from Adolescents and Children.                 
*** Indicates that all groups are significantly different from each other. 
 
Significant differences are present for both the biomarker concentration in urine 
(µg/L) and when adjusting for creatinine (µg/g).  For the unadjusted urinary biomarker 
concentration, children and adolescents are significantly elevated when compared to 
adults; however, there is no significant difference between children and adolescents 
within the same group.  All three groups had a significant difference when adjusting for 
creatinine.  
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Figure 15: Graph of Arithmetic Mean Height for Detects Versus Non-Detects for           
3,5,6-Trichloropyridinol, Ages 6-11.  cm= Centimeter. 
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Table 15: Student’s t-test Comparing Detects Versus Non-Detects for Arithmetic Mean 
of Height for 3,5,6-Trichloropyridinol. 
 
Age Detecta Mean (cmb) LCLc UCLd SDe nf pg 
6 Yes 120.4 119 121.7 5.90 74 0.096 No 117.5 114.6 120.4 5.05 14 
7 Yes 125.9 124.7 127.1 5.54 86 0.165 No 128.8 124.7 132.8 7.90 17 
8 Yes 132.5 130.7 134.3 8.02 77 0.682 No 131.4 126.9 135.9 6.30 10 
9 Yes 137.2 135.7 138.7 7.45 98 0.492 No 135.8 132.7 138.9 5.28 14 
10 Yes 144 141.9 146 8.24 67 0.685 No 142.9 138.8 147 6.04 11 
11 Yes 152.6 150.9 154.3 8.14 88 0.360 No 150.6 146.6 154.5 7.14 15 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(cm) = Centimeters; 
c(LCL) = Lower Confidence Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard 
Deviation; f(n) = Number in Sample; g(p) = Level of Significance at p= 0.05 Level 
 
There are no significant differences at the p < 0.05 level between detect and non-
detect urinary concentrations of 3,5,6-trichloropyridinol when evaluating variations in 
children’s height.  
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Figure 16: Graph of Arithmetic Mean Weight for Detects Versus Non-Detects for 3,5,6-
Trichloropyridinol, Ages 6-11.  Kg= Kilograms 
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Table 16: Student’s t-test Comparing Detects Versus Non-Detects for Arithmetic Mean 
of Weight for 3,5,6-Trichloropyridinol. 
 
Age Detecta Mean (Kgb) LCLc UCLd SDe nf pg 
6 Yes 23.86 22.91 24.81 4.09 74 0.201 No 22.29 19.59 24.98 4.66 14 
7 Yes 27.07 25.91 28.23 5.37 85 0.080 No 31.56 26.58 36.55 9.69 17 
8 Yes 33.07 30.69 35.45 10.34 75 0.258 No 29.23 24.37 34.09 6.79 10 
9 Yes 34.83 32.78 36.87 10.10 96 0.532 No 33.06 28.50 37.61 7.89 14 
10 Yes 41.49 38.22 44.77 13.42 67 0.453 No 38.34 32.74 43.93 8.32 11 
11 Yes 51.65 47.52 55.77 19.11 85 0.640 No 49.20 40.58 57.82 15.56 15 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(Kg) = Kilograms; 
c(LCL) = Lower Confidence Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard 
Deviation; f(n) = Number in Sample; g(p) = Level of Significance at p= 0.05 Level 
 
There are no significant differences at the p < 0.05 level between detect and non-
detect urinary concentrations of 3,5,6-trichloropyridinol when evaluating variations in 
children’s weight.  
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Table 17: 3,5,6-Trichloropyridinol Female Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 18.76 18.15 19.38 9.29 874 5 102 0.177 No 19.58 18.52 20.64 9.90 340 5 102 
Albumin (g/dL)j Yes 4.17 4.14 4.19 0.34 874 2.6 5 0.661 No 4.16 4.12 4.20 0.36 340 2.6 5 
Alkaline Phosphatase (U/L) Yes 83.76 80.85 86.67 43.90 874 30 424 0.002 No 76.11 72.35 79.87 35.25 340 24 269 
Aspartate Transaminase (U/L) Yes 21.56 21.07 22.04 7.34 874 9 114 0.296 No 22.05 21.26 22.83 7.35 340 7 84 
Bicarbonate (mmol/L)k Yes 22.76 22.61 22.90 2.22 874 16 29 0.001 No 23.24 23.01 23.47 2.18 340 18 29 
Bilirubin (mg/dL)l Yes 0.66 0.64 0.67 0.22 874 0.2 2.1 0.876 No 0.66 0.64 0.68 0.20 340 0.2 1.6 
Blood Urea Nitrogen (mg/dL) Yes 11.99 11.58 12.41 6.23 874 2 122 0.912 No 11.95 11.37 12.53 5.45 340 3 53 
Total Calcium (mg/dL) Yes 9.43 9.40 9.45 0.39 874 8.1 11 0.095 No 9.47 9.43 9.51 0.39 340 8.3 10.7 
Chloride (mmol/L) Yes 103.20 103.00 103.40 2.61 874 89 111 0.034 No 102.80 102.50 103.10 2.87 339 89 113 
Cholesterol (mg/dL) Yes 186.90 184.10 189.70 42.13 874 91 460 <.0001 No 202.50 197.50 207.60 47.30 340 90 476 
Creatinine (mg/dL) Yes 0.72 0.71 0.74 0.22 874 0.3 4.4 0.019 No 0.76 0.73 0.78 0.23 340 0.3 3.1 
γ Glutamyl Transferase (U/L) Yes 19.54 18.28 20.80 18.96 874 4 266 0.087 No 22.27 19.41 25.14 26.88 340 6 369 
Globulin (mg/dL) Yes 3.18 3.15 3.21 0.40 874 2.3 5.4 0.062 No 3.13 3.09 3.17 0.39 340 2.2 4.6 
Glucose (mg/dL) Yes 89.21 87.47 90.95 26.25 874 34 453 0.171 No 92.16 88.30 96.03 36.20 340 30 521 
Iron (mg/dL) Yes 82.01 79.56 84.47 37.03 874 7 240 0.638 No 83.14 79.11 87.16 37.75 340 12 268 
Lactate Dehydrogenase (U/L) Yes 130.80 129.00 132.70 28.33 874 58 470 0.745 No 130.20 127.20 133.30 28.62 339 51 329 
Osmolality (mmol/Kg)m Yes 275.50 275.10 275.90 5.53 874 248 310 0.989 No 275.50 274.90 276.10 5.55 340 252 294 
Phosphorus (mg/dL) Yes 4.00 3.96 4.04 0.58 874 2.3 6.1 0.019 No 3.92 3.87 3.98 0.53 340 2.3 5.8 
Potassium (mmol/L) Yes 3.98 3.96 4.00 0.33 874 2.6 6 0.179 No 4.01 3.97 4.05 0.36 340 2.9 5.3 
Total Protein (g/dL) Yes 7.35 7.31 7.38 0.48 874 5.5 9.5 0.068 No 7.29 7.24 7.34 0.50 340 5.9 9.1 
Sodium (mmol/L) Yes 138.30 138.20 138.50 2.51 874 124 147 0.551 No 138.30 138.00 138.50 2.53 340 125 145 
Triglycerides (mg/dL) Yes 116.00 110.80 121.30 78.40 874 23 742 0.013 No 131.60 120.60 142.70 103.70 340 28 1077 
Uric Acid (mg/dL) Yes 4.50 4.42 4.58 1.19 874 0.4 10.9 0.018 No 4.70 4.55 4.85 1.39 340 2.4 13.9 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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Table 18: 3,5,6-Trichloropyridinol Male Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 26.67 25.42 27.93 19.08 892 7 243 0.861 No 26.46 24.42 28.50 13.93 181 9 109 
Albumin (g/dL)j Yes 4.39 4.37 4.41 0.31 892 2.1 5.3 0.750 No 4.38 4.34 4.42 0.29 181 3.2 5.3 
Alkaline Phosphatase (U/L) Yes 104.70 99.81 109.50 73.70 892 19 589 0.112 No 94.94 83.22 106.70 79.95 181 37 617 
Aspartate Transaminase (U/L) Yes 26.41 25.57 27.24 12.68 892 9 187 0.426 No 27.23 25.34 29.12 12.89 181 13 118 
Bicarbonate (mmol/L)k Yes 23.97 23.83 24.11 2.14 892 15 29 0.084 No 24.27 23.97 24.58 2.08 181 18 30 
Bilirubin (mg/dL)l Yes 0.82 0.80 0.84 0.32 892 0.3 3.5 0.349 No 0.80 0.76 0.84 0.27 181 0.3 2.4 
Blood Urea Nitrogen (mg/dL) Yes 14.16 13.81 14.50 5.26 892 3 48 0.204 No 13.61 12.80 14.42 5.52 181 4 42 
Total Calcium (mg/dL) Yes 9.55 9.53 9.58 0.40 892 7.2 11.3 0.664 No 9.54 9.48 9.60 0.40 181 7.6 10.6 
Chloride (mmol/L) Yes 102.50 102.30 102.70 2.57 892 83 112 0.235 No 102.20 101.80 102.60 2.69 181 93 108 
Cholesterol (mg/dL) Yes 184.90 182.10 187.80 43.86 892 71 566 0.308 No 188.60 182.30 194.90 42.80 181 86 407 
Creatinine (mg/dL) Yes 0.96 0.95 0.98 0.26 892 0.4 4.4 0.303 No 0.99 0.95 1.02 0.25 181 0.4 2.6 
γ Glutamyl Transferase (U/L) Yes 30.12 28.04 32.19 31.59 892 6 482 0.387 No 32.39 27.24 37.54 35.10 181 6 394 
Globulin (mg/dL) Yes 3.08 3.05 3.11 0.43 891 1.6 5.6 0.377 No 3.04 2.97 3.11 0.48 181 2 5.9 
Glucose (mg/dL) Yes 95.24 93.19 97.29 31.18 892 58 707 0.669 No 96.33 91.75 100.90 31.25 181 69 382 
Iron (mg/dL) Yes 96.50 93.94 99.05 38.84 892 12 333 0.298 No 99.81 93.96 105.70 39.89 181 18 223 
Lactate Dehydrogenase (U/L) Yes 138.50 136.30 140.80 34.58 892 52 399 0.037 No 133.70 129.80 137.60 26.88 181 72 247 
Osmolality (mmol/Kg)m Yes 278.00 277.60 278.30 5.30 892 218 299 0.061 No 277.20 276.40 277.90 5.40 181 261 298 
Phosphorus (mg/dL) Yes 3.92 3.88 3.97 0.71 892 2.4 6.6 0.332 No 3.87 3.77 3.96 0.64 181 2.4 6.6 
Potassium (mmol/L) Yes 4.12 4.10 4.14 0.35 892 3.1 5.5 0.523 No 4.14 4.09 4.19 0.34 181 3.2 5.4 
Total Protein (g/dL) Yes 7.47 7.44 7.50 0.46 891 5.3 9.4 0.269 No 7.42 7.35 7.50 0.49 181 6.2 9.8 
Sodium (mmol/L) Yes 139.10 138.90 139.20 2.58 892 108 147 0.077 No 138.70 138.40 139.00 2.34 181 131 144 
Triglycerides (mg/dL) Yes 145.00 132.30 157.70 193.60 892 21 3854 0.617 No 137.20 110.10 164.20 184.50 181 28 2337 
Uric Acid (mg/dL) Yes 6.00 5.91 6.09 1.32 892 1.5 13.4 0.905 No 5.99 5.79 6.19 1.37 181 2.6 11 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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Table 19: 3,5,6-Trichloropyridinol Overall Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 22.76 22.03 23.48 15.56 1766 5 243 0.218 No 21.97 20.94 22.99 11.91 521 5 109 
Albumin (g/dL)j Yes 4.28 4.26 4.29 0.34 1766 2.1 5.3 0.011 No 4.23 4.20 4.26 0.36 521 2.6 5.3 
Alkaline Phosphatase (U/L) Yes 94.31 91.43 97.19 61.68 1766 19 589 <.0001 No 82.65 77.86 87.45 55.71 521 24 617 
Aspartate Transaminase (U/L) Yes 24.01 23.51 24.50 10.66 1766 9 187 0.755 No 23.85 22.99 24.70 9.94 521 7 118 
Bicarbonate (mmol/L)k Yes 23.37 23.26 23.47 2.26 1766 15 29 0.041 No 23.60 23.41 23.79 2.20 521 18 30 
Bilirubin (mg/dL)l Yes 0.74 0.73 0.76 0.28 1766 0.2 3.5 0.010 No 0.71 0.69 0.73 0.24 521 0.2 2.4 
Blood Urea Nitrogen (mg/dL) Yes 13.09 12.81 13.36 5.86 1766 2 122 0.053 No 12.53 12.05 13.00 5.53 521 3 53 
Total Calcium (mg/dL) Yes 9.49 9.47 9.51 0.40 1766 7.2 11.3 0.910 No 9.49 9.46 9.53 0.39 521 7.6 10.7 
Chloride (mmol/L) Yes 102.80 102.70 103.00 2.61 1766 83 112 0.103 No 102.60 102.40 102.80 2.82 520 89 113 
Cholesterol (mg/dL) Yes 185.90 183.90 187.90 43.01 1766 71 566 <.0001 No 197.70 193.70 201.70 46.22 521 86 476 
Creatinine (mg/dL) Yes 0.84 0.83 0.86 0.27 1766 0.3 4.4 0.529 No 0.84 0.81 0.86 0.26 521 0.3 3.1 
γ Glutamyl Transferase (U/L) Yes 24.88 23.64 26.13 26.64 1766 4 482 0.539 No 25.79 23.18 28.40 30.34 521 6 394 
Globulin (mg/dL) Yes 3.13 3.11 3.15 0.42 1765 1.6 5.6 0.203 No 3.10 3.07 3.14 0.42 521 2 5.9 
Glucose (mg/dL) Yes 92.26 90.90 93.61 29.00 1766 34 707 0.416 No 93.61 90.64 96.59 34.59 521 30 521 
Iron (mg/dL) Yes 89.33 87.53 91.13 38.63 1766 7 333 0.835 No 88.93 85.55 92.31 39.28 521 12 268 
Lactate Dehydrogenase (U/L) Yes 134.70 133.20 136.20 31.86 1766 52 470 0.024 No 131.40 129.00 133.90 28.05 520 51 329 
Osmolality (mmol/Kg)m Yes 276.70 276.50 277.00 5.56 1766 218 310 0.015 No 276.10 275.60 276.50 5.55 521 252 298 
Phosphorus (mg/dL) Yes 3.96 3.93 3.99 0.65 1766 2.3 6.6 0.042 No 3.90 3.85 3.95 0.57 521 2.3 6.6 
Potassium (mmol/L) Yes 4.05 4.03 4.07 0.35 1766 2.6 6 0.826 No 4.05 4.02 4.09 0.36 521 2.9 5.4 
Total Protein (g/dL) Yes 7.41 7.38 7.43 0.47 1765 5.3 9.5 0.003 No 7.34 7.29 7.38 0.50 521 5.9 9.8 
Sodium (mmol/L) Yes 138.70 138.60 138.80 2.57 1766 108 147 0.017 No 138.40 138.20 138.60 2.47 521 125 145 
Triglycerides (mg/dL) Yes 130.70 123.70 137.60 148.90 1766 21 3854 0.680 No 133.50 121.70 145.30 137.10 521 28 2337 
Uric Acid (mg/dL) Yes 5.26 5.19 5.32 1.47 1766 0.4 13.4 0.137 No 5.15 5.02 5.28 1.51 521 2.4 13.9 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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4.3.1.3 Logistic Regression 
 
Table 20: Logistic Regression for 3,5,6-Trichloropyridinol. 
 
 
Detecta  
(DFb=1) 
Detect, Non-Hispanic White 
(DF=1) 
Detect, Female  
(DF=1) 
Age 
β=-0.0145 
Wald χ2=53.74 
p<0.0001 
OR=0.986 
  
Mexican American  
β=0.221 
Wald χ2=4.86 
p=0.028 
OR=1.31 
 
Non-Hispanic 
Black  
β=-0.317 
Wald χ2=3.50 
p=0.062 
OR=0.765 
 
Other Hispanic  
β=0.272 
Wald χ2=7.20 
p=0.007 
OR=1.38 
 
Other  
β=-0.128 
Wald χ2=0.500 
p=0.479 
OR=0.924 
 
Male   
β=0.28 
Wald χ2=36.28 
p<0.0001 
OR=1.75 
a(Detect) =  Detectable Level of Biomarker in the Urine Sample, used as a reference 
category in the Model;  b(DF)= Degree of Freedom. Significant differences are highlight 
in Bold. 
 
The overall model fit was significant, with the Likelihood χ2= 119.4, p <0.0001 
and the R2 Max = 0.0602.  The Hosmer and Lemeshow goodness-of-fit test resulted in a 
χ2= 12.2, p= 0.144, indicating that the data from the independent variables fit the model 
moderately well.  The listed detects at the row headers are the reference groups for each 
sub-category. When stratifying for individual groups, age does not seem to have an effect 
on the detection of a biomarker (β=-0.0145 and OR=0.986, p< 0.0001).  Mexican 
Americans (β=0.221 and OR=1.31, p=0.028) and Other Hispanics (β=0.272 and OR= 
1.38, p=0.007) had a slightly higher change in the regression coefficient and higher odds 
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of having a detectable level of the biomarker than Non-Hispanic Whites (reference 
group).  Males had a higher change in the regression coefficient and higher odds of 
having a detectable level of biomarker than females (β=0.28 and OR= 1.75, p< 0.0001).   
 
4.3.2 Methyl Parathion Biomarker: Paranitrophenol (PNP) 
4.3.2.1 Descriptive Statistics 
The information covered in the following figures and tables characterizes the 
exposures to methyl parathion in the overall sample and in various subgroups. 
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Figure 17: Comparison of Means for Paranitrophenol.  µg/l= Micrograms per Liter; 
µg/g= Micrograms per Gram. Adjusting for creatinine results in means (both geometric 
and arithmetic) that are lower than if using the concentration of the PNP biomarker in 
urine (µg/L) alone.  Limit of Detection (LOD) for PNP in sample was 0.1 µg/L. 
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Table 21: Descriptive Statistics for Paranitrophenol. 
 
 Biomarker (µg/L)a    Creatinine Adjusted (µg/g)b  
 
Geometric 
 Mean 
Arithmetic  
Mean   
Geometric 
 Mean 
Arithmetic 
 Mean 
nc 2975 2975  N 2973 2973 
Mean 0.367 1.16  Mean 0.352 0.905 
LCLd 0.346 1.08  LCL 0.335 0.839 
UCLe 0.389 1.25  UCL 0.371 0.970 
SDf 5.11 2.35  SD 4.18 1.83 
P25g < LODh < LOD  P25 0.096 0.096 
P50i 0.7 0.7  P50 0.427 0.427 
P75j 1.46 1.46  P75 1.08 1.08 
P90k 2.82 2.82  P90 2.10 2.10 
P95l 3.92 3.92  P95 3.20 3.20 
Minm 0.07 0.07  Min 0.0124 0.0124 
Maxn 59.89 59.89  Max 51.26 51.26 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(n) = Number in 
Sample; d(LCL) = Lower Confidence Limit; e(UCL) = Upper Confidence Limit; f(SD) = 
Standard Deviation; g(P25) = Lower Quartile; h(LOD) = Limit of Detection, at 0.1 µg/L.; 
i(P50) = Median; j(P75) = Upper Quartile; k(P90) = 90th Percentile; l(P95) =95th 
Percentile; m(Min) = Minimum n(Max) = Maximum 
 
Adjusting for creatinine results in means (both geometric and arithmetic) that are 
lower than if using the concentration of the biomarker in urine (µg/L) alone, but not by a 
large margin.   
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Geometric Mean for Detects of Paranitrophenol
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Figure 18: Comparison of Detectable Geometric Mean Concentrations for 
Paranitrophenol.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
 
Table 22: Descriptive Statistics for Detectable Levels of Paranitrophenol. 
 
  GMc LCLd UCLe SDf Median ng 
Biomarker (µg/L)a 1.58 1.53 1.64 1.97 1.39 1580 
Creatinine Adjusted (µg/g)b 1.11 1.06 1.15 2.16 1.02 1578 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(GM) = Geometric 
Mean; d(LCL) = Lower Confidence Limit; e(UCL) = Upper Confidence Limit; f(SD) = 
Standard Deviation; g(n) = Number in Sample 
 
The geometric mean was determined for the 53.1% of the individuals that had a 
detectable level of biomarker in their urine sample.  Based on this analysis, the geometric 
mean for only detectable levels of the biomarker was 1.2 µg/L higher that the overall 
geometric mean.  
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4.3.2.2 Comparative Statistics 
 
Male and Female Geometric Mean Levels for Paranitrophenol
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Figure 19: Comparison of Geometric Mean Values of Males versus Females for 
Paranitrophenol.   µg/l= Micrograms per Liter; µg/g= Micrograms per Gram.  Color-
coded “*” indicates males are significantly different from females. 
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Table 23: Student’s t-test Comparing Geometric Means of Males Versus Females for 
Paranitrophenol. 
 
Biomarker (µg/L)a        
 GMb LCLc UCLd SDe Median nf (D/ND)g Ph 
Male 0.447 0.410 0.487 5.14 0.830 1395 (823/572) <0.0001 Female 0.308 0.284 0.333 4.99 < LODi 1580 (757/823) 
Total      2975  
        
Creatinine Adjusted (µg/g)j        
  GM LCL UCL SD Median n p 
Male 0.363 0.336 0.392 4.27 0.519 1395 0.276 Female 0.343 0.320 0.368 4.35 0.333 1578 
Total      2973  
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation;  f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(LOD) = Limit of Detection, at 0.1 
µg/L; j(µg/g) = Micrograms per Gram 
 
Males have a statistically significant higher GM when compared to females, but 
only when using the unadjusted biomarker concentration in urine (µg/L).  Adjusting for 
dilution negates any significant difference.  
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Ethnicity Geometric Mean for Paranitrophenol
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Figure 20: Comparison of Geometric Mean Values of Ethnic Groups for 
Paranitrophenol.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. Color-coded 
“**” indicates which groups are significantly different from each other.  
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Table 24: One-Way ANOVA and Tukey Analysis Comparing Geometric Means of 
Ethnic Groups for Paranitrophenol. 
 
Biomarker (µg/L)a       
 GMb LCLc UCLd SDe nf (D/ND)g Ph 
Mexican American* 0.353 0.012 0.695 4.75 744 (402/342) 
<0.0001 
Non-Hispanic Black* 0.486 0.095 0.877 5.42 738 (439/299) 
Non-Hispanic White* 0.319 0.034 0.603 5.12 1247 (605/642) 
Other Hispanic 0.306 -0.537 1.15 4.83 126 (62/64) 
Other 0.424 -0.418 1.27 4.71 120 (72/48) 
Total     2975  
       
Creatinine Adjusted (µg/g)i       
 GM LCL UCL SD n p 
Mexican American 0.350 0.066 0.634 3.95 744 
0.131 
Non-Hispanic Black 0.364 0.036 0.692 4.54 737 
Non-Hispanic White 0.344 0.113 0.576 4.16 1246 
Other Hispanic 0.292 -0.443 1.03 4.21 126 
Other 0.461 -0.161 1.08 3.48 120 
Total     2973  
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram.     
* Indicates groups that are significantly different from each other. 
 
Mexican Americans, Non-Hispanic Blacks and Non-Hispanic Whites are 
significantly different compared to each other when using the unadjusted biomarker 
concentration (µg/L).   No difference was observed when adjusting for creatinine.  
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Age Groups Geometric Mean for Paranitrophenol
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Figure 21: Comparison of Geometric Mean Values of Age Groups for Paranitrophenol. 
µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. Color-coded “*” indicates 
which groups are significantly different from each other. 
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Table 25: One-Way ANOVA and Tukey Analysis Comparing Geometric Means of   
Age Groups for Paranitrophenol. 
 
Biomarker (µg/L)a        
 GMb LCLc UCLd SDe nf (D/ND)g Ph 
Children* 0.455 0.038 0.873 5.06 565 (338/227) 
<0.0001 Adolescent* 0.399 0.043 0.755 4.91 732 (414/318) 
Adult** 0.329 0.081 0.576 5.18 1678 (828/850) 
Total     2975  
       
Creatinine Adjusted (µg/g)i       
 GM LCL UCL SD n p 
Children*** 0.549 0.210 0.887 4.10 565 
<0.0001 Adolescent 0.295 0.004 0.586 4.02 731 
Adult 0.328 0.129 0.527 4.16 1677 
Total     2973  
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram.     
* Indicates group is significantly different from Adults.                                                     
** Indicates that group is significantly different from Adolescents and Children.                 
*** Indicates that Children were significantly different from Adolescents and Adults. 
 
Significant differences exist for both the urinary concentration of the biomarker 
and when adjusting for creatinine.  For the unadjusted biomarker in urine, children and 
adolescents were significantly different from the adult group, but were not significantly 
different from each other.  Children in the creatinine-adjusted analysis were significantly 
different from adolescents and adults, but adolescents not significantly different from 
adults.  
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Figure 22: Graph of Arithmetic Mean Height for Detects Versus Non-Detects for 
Paranitrophenol, Ages 6-11.  cm= Centimeter.  = Significantly different means. 
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Table 26: Student’s t-test Comparing Detects Versus Non-Detects for Arithmetic Mean 
of Height for Paranitrophenol. 
 
Age Detecta Mean (cmb) LCLc UCLd SDe nf pg 
6 Yes 120.7 118.9 122.4 6.43 54 0.100 No 118.7 117.1 120.3 4.60 34 
7 Yes 126.5 125 128 5.90 62 0.759 No 126.1 124 128.1 6.37 40 
8 Yes 130.9 128.7 133.2 7.83 49 0.046 No 134.3 131.8 136.7 7.48 38 
9 Yes 137.3 135.4 139.3 7.63 62 0.619 No 136.6 134.7 138.6 6.67 48 
10 Yes 144.4 141.9 146.9 8.56 47 0.512 No 143.2 140.5 145.8 7.04 29 
11 Yes 153.7 151.6 155.8 8.34 63 0.022 No 149.9 147.6 152.3 7.04 37 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(cm) = Centimeters; 
c(LCL) = Lower Confidence Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard 
Deviation; f(n) = Number in Sample; g(p) = Level of Significance at p= 0.05 Level 
(highlighted in Bold) 
 
There is a significantly higher mean height for age 8 non-detects as compared to 
those with a detect for the biomarker.  Children with a recorded detect age 11 had a 
significantly higher mean height than those children in the same age group that did not 
have a detect.  
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Paranitrophenol Mean Child Weight
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Figure 23: Graph of Arithmetic Mean Weight for Detects Versus Non-Detects for 
Paranitrophenol, Ages 6-11.  Kg= Kilograms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
Table 27: Student’s t-test Comparing Detects Versus Non-Detects for Arithmetic Mean 
of Weight for Paranitrophenol. 
 
Age Detecta Mean (Kgb) LCLc UCLd SDe nf pg 
6 Yes 23.86 22.62 25.11 4.56 54 0.476 No 23.20 21.95 24.45 3.58 34 
7 Yes 28.19 26.64 29.75 6.11 62 0.470 No 27.23 24.93 29.53 7.09 39 
8 Yes 31.96 28.92 34.99 10.46 48 0.491 No 33.48 30.30 36.66 9.54 37 
9 Yes 34.70 31.94 37.45 10.68 60 0.864 No 34.37 31.79 36.94 8.86 48 
10 Yes 41.56 37.73 45.38 13.03 47 0.711 No 40.41 35.41 45.41 13.14 29 
11 Yes 52.89 47.76 58.02 20.02 61 0.319 No 48.93 43.31 54.54 16.60 36 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(Kg) = Kilograms; 
c(LCL) = Lower Confidence Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard 
Deviation; f(n) = Number in Sample; g(p) = Level of Significance at p= 0.05 Level 
 
There are no significant differences at the p < 0.05 level between detect and non-
detect urinary concentrations of paranitrophenol when evaluating variations in children’s 
weight.  
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Table 28: Paranitrophenol Female Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 18.70 17.87 19.53 9.78 538 7 102 0.375 No 19.18 18.51 19.86 8.87 666 5 83 
Albumin (g/dL)j Yes 4.15 4.12 4.18 0.33 538 2.6 5 0.196 No 4.18 4.15 4.20 0.36 666 2.6 5 
Alkaline Phosphatase (U/L) Yes 83.90 80.06 87.75 45.43 538 30 424 0.084 No 79.63 76.69 82.57 38.64 666 24 341 
Aspartate Transaminase (U/L) Yes 21.48 20.83 22.13 7.70 538 9 114 0.399 No 21.84 21.31 22.37 6.93 666 7 84 
Bicarbonate (mmol/L)k Yes 23.01 22.83 23.19 2.16 538 16 29 0.083 No 22.79 22.61 22.96 2.27 666 16 29 
Bilirubin (mg/dL)l Yes 0.65 0.63 0.66 0.20 538 0.2 2.1 0.083 No 0.67 0.65 0.68 0.22 666 0.2 1.9 
Blood Urea Nitrogen (mg/dL) Yes 11.99 11.57 12.41 4.96 538 2 45 0.973 No 11.98 11.46 12.49 6.79 666 2 122 
Total Calcium (mg/dL) Yes 9.43 9.40 9.46 0.38 538 8.1 10.7 0.516 No 9.45 9.42 9.48 0.40 666 8.3 11 
Chloride (mmol/L) Yes 103.20 102.90 103.40 2.60 538 93 111 0.375 No 103.00 102.80 103.20 2.76 665 89 113 
Cholesterol (mg/dL) Yes 187.10 183.60 190.50 41.28 538 91 334 0.003 No 194.60 191.10 198.10 46.08 666 90 476 
Creatinine (mg/dL) Yes 0.73 0.72 0.75 0.19 538 0.3 2.3 0.820 No 0.73 0.71 0.75 0.25 666 0.3 4.4 
γ Glutamyl Transferase (U/L) Yes 20.59 18.82 22.36 20.94 538 5 266 0.705 No 20.12 18.44 21.80 22.08 666 4 369 
Globulin (mg/dL) Yes 3.17 3.14 3.21 0.40 538 2.2 5.4 0.478 No 3.16 3.13 3.19 0.39 666 2.2 4.8 
Glucose (mg/dL) Yes 92.03 89.15 94.91 33.99 538 50 521 0.044 No 88.48 86.56 90.40 25.23 666 30 453 
Iron (mg/dL) Yes 81.59 78.38 84.81 37.99 538 8 249 0.493 No 83.07 80.29 85.85 36.54 666 7 268 
Lactate Dehydrogenase (U/L) Yes 129.40 127.10 131.70 26.96 538 51 277 0.230 No 131.40 129.10 133.60 29.49 665 58 470 
Osmolality (mmol/Kg)m Yes 275.80 275.30 276.20 5.37 538 250 297 0.100 No 275.30 274.80 275.70 5.67 666 248 310 
Phosphorus (mg/dL) Yes 4.02 3.97 4.07 0.59 538 2.3 5.7 0.053 No 3.95 3.91 3.99 0.55 666 2.3 6.1 
Potassium (mmol/L) Yes 3.99 3.96 4.02 0.33 538 3.1 5.5 0.924 No 3.99 3.96 4.01 0.35 666 2.6 6 
Total Protein (g/dL) Yes 7.32 7.28 7.37 0.49 538 5.5 9.5 0.737 No 7.33 7.30 7.37 0.48 666 5.9 9.1 
Sodium (mmol/L) Yes 138.40 138.20 138.60 2.42 538 125 145 0.229 No 138.20 138.00 138.40 2.60 666 124 147 
Triglycerides (mg/dL) Yes 121.90 114.20 129.50 90.47 538 23 742 0.644 No 119.50 113.20 125.90 83.24 666 28 1077 
Uric Acid (mg/dL) Yes 4.57 4.46 4.67 1.26 538 0.4 10.9 0.826 No 4.55 4.46 4.64 1.25 666 1.8 13.9 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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Table 29: Paranitrophenol Male Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 26.54 25.04 28.04 18.97 620 8 243 0.954 No 26.61 24.97 28.24 17.40 436 7 165 
Albumin (g/dL)j Yes 4.38 4.35 4.40 0.30 620 2.1 5.3 0.200 No 4.40 4.37 4.43 0.31 436 2.6 5.3 
Alkaline Phosphatase (U/L) Yes 102.10 96.44 107.70 71.20 620 19 617 0.872 No 102.80 95.69 109.90 75.50 436 33 515 
Aspartate Transaminase (U/L) Yes 26.55 25.50 27.59 13.28 620 9 187 0.950 No 26.50 25.36 27.63 12.05 436 12 118 
Bicarbonate (mmol/L)k Yes 24.00 23.82 24.17 2.16 620 15 29 0.903 No 24.01 23.81 24.21 2.10 436 17 30 
Bilirubin (mg/dL)l Yes 0.82 0.79 0.84 0.30 620 0.3 2.9 0.518 No 0.83 0.80 0.86 0.32 436 0.3 3.5 
Blood Urea Nitrogen (mg/dL) Yes 14.25 13.84 14.67 5.28 620 3 48 0.103 No 13.72 13.24 14.20 5.10 436 3 41 
Total Calcium (mg/dL) Yes 9.53 9.50 9.56 0.38 620 7.2 10.6 0.022 No 9.59 9.55 9.63 0.42 436 7.6 11.3 
Chloride (mmol/L) Yes 102.60 102.40 102.80 2.63 620 83 111 0.003 No 102.20 101.90 102.40 2.55 436 93 112 
Cholesterol (mg/dL) Yes 183.60 180.00 187.20 45.40 620 71 566 0.078 No 188.40 184.50 192.40 41.69 436 86 402 
Creatinine (mg/dL) Yes 0.97 0.95 0.99 0.26 620 0.4 4.4 0.871 No 0.97 0.94 0.99 0.24 436 0.4 2.5 
γ Glutamyl Transferase (U/L) Yes 30.34 27.74 32.93 32.89 620 6 482 0.788 No 30.88 27.90 33.87 31.73 436 6 394 
Globulin (mg/dL) Yes 3.08 3.04 3.11 0.47 620 1.6 5.9 0.765 No 3.07 3.03 3.10 0.39 435 2 4.4 
Glucose (mg/dL) Yes 94.51 92.73 96.29 22.60 620 65 295 0.312 No 96.65 92.89 100.40 39.97 436 68 707 
Iron (mg/dL) Yes 95.80 92.76 98.84 38.58 620 12 276 0.180 No 99.07 95.34 102.80 39.60 436 18 333 
Lactate Dehydrogenase (U/L) Yes 136.30 133.80 138.80 31.70 620 52 355 0.205 No 139.00 135.60 142.40 35.74 436 75 399 
Osmolality (mmol/Kg)m Yes 278.00 277.60 278.40 5.51 620 218 299 0.126 No 277.50 277.00 278.00 4.99 436 261 298 
Phosphorus (mg/dL) Yes 3.93 3.88 3.99 0.69 620 2.5 6.6 0.234 No 3.88 3.81 3.95 0.70 436 2.4 6.6 
Potassium (mmol/L) Yes 4.12 4.09 4.15 0.36 620 3.1 5.5 0.937 No 4.12 4.09 4.15 0.34 436 3.2 5.3 
Total Protein (g/dL) Yes 7.45 7.42 7.49 0.48 620 5.3 9.8 0.569 No 7.47 7.43 7.51 0.44 435 5.9 8.7 
Sodium (mmol/L) Yes 139.10 138.90 139.30 2.72 620 108 147 0.146 No 138.90 138.60 139.10 2.28 436 131 146 
Triglycerides (mg/dL) Yes 140.90 127.00 154.70 175.90 620 21 2677 0.550 No 148.30 128.00 168.60 215.60 436 27 3854 
Uric Acid (mg/dL) Yes 5.98 5.88 6.08 1.26 620 1.5 13.4 0.643 No 6.02 5.89 6.15 1.40 436 2.6 11 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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Table 30: Paranitrophenol Overall Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 22.90 21.98 23.81 15.88 1158 7 243 0.208 No 22.12 21.33 22.91 13.43 1102 5 165 
Albumin (g/dL)j Yes 4.27 4.25 4.29 0.33 1158 2.1 5.3 0.646 No 4.27 4.24 4.29 0.36 1102 2.6 5.3 
Alkaline Phosphatase (U/L) Yes 93.62 90.09 97.16 61.26 1158 19 617 0.053 No 88.80 85.41 92.18 57.29 1102 24 515 
Aspartate Transaminase (U/L) Yes 24.19 23.54 24.84 11.32 1158 9 187 0.247 No 23.68 23.12 24.25 9.57 1102 7 118 
Bicarbonate (mmol/L)k Yes 23.54 23.41 23.66 2.22 1158 15 29 0.005 No 23.27 23.14 23.41 2.29 1102 16 30 
Bilirubin (mg/dL)l Yes 0.74 0.72 0.75 0.27 1158 0.2 2.9 0.612 No 0.73 0.72 0.75 0.28 1102 0.2 3.5 
Blood Urea Nitrogen (mg/dL) Yes 13.20 12.90 13.50 5.25 1158 2 48 0.028 No 12.67 12.30 13.04 6.23 1102 2 122 
Total Calcium (mg/dL) Yes 9.48 9.46 9.51 0.38 1158 7.2 10.7 0.287 No 9.50 9.48 9.53 0.41 1102 7.6 11.3 
Chloride (mmol/L) Yes 102.90 102.70 103.00 2.63 1158 83 111 0.073 No 102.70 102.50 102.80 2.71 1101 89 113 
Cholesterol (mg/dL) Yes 185.20 182.70 187.70 43.55 1158 71 566 0.0002 No 192.20 189.50 194.80 44.48 1102 86 476 
Creatinine (mg/dL) Yes 0.86 0.84 0.87 0.26 1158 0.3 4.4 0.002 No 0.82 0.81 0.84 0.27 1102 0.3 4.4 
γ Glutamyl Transferase (U/L) Yes 25.81 24.17 27.45 28.39 1158 5 482 0.218 No 24.38 22.79 25.96 26.83 1102 4 394 
Globulin (mg/dL) Yes 3.12 3.10 3.15 0.44 1158 1.6 5.9 0.967 No 3.12 3.10 3.14 0.39 1101 2 4.8 
Glucose (mg/dL) Yes 93.36 91.72 95.00 28.48 1158 50 521 0.198 No 91.71 89.81 93.61 32.12 1102 30 707 
Iron (mg/dL) Yes 89.20 86.95 91.44 38.94 1158 8 276 0.902 No 89.40 87.12 91.68 38.57 1102 7 333 
Lactate Dehydrogenase (U/L) Yes 133.10 131.40 134.80 29.78 1158 51 355 0.323 No 134.40 132.50 136.30 32.31 1101 58 470 
Osmolality (mmol/Kg)m Yes 277.00 276.60 277.30 5.56 1158 218 299 0.0004 No 276.10 275.80 276.50 5.52 1102 248 310 
Phosphorus (mg/dL) Yes 3.97 3.93 4.01 0.64 1158 2.3 6.6 0.075 No 3.92 3.89 3.96 0.62 1102 2.3 6.6 
Potassium (mmol/L) Yes 4.06 4.04 4.08 0.36 1158 3.1 5.5 0.170 No 4.04 4.02 4.06 0.35 1102 2.6 6 
Total Protein (g/dL) Yes 7.39 7.36 7.42 0.49 1158 5.3 9.8 0.768 No 7.39 7.36 7.42 0.47 1101 5.9 9.1 
Sodium (mmol/L) Yes 138.80 138.60 138.90 2.60 1158 108 147 0.008 No 138.50 138.30 138.60 2.49 1102 124 147 
Triglycerides (mg/dL) Yes 132.00 123.80 140.30 143.00 1158 21 2677 0.858 No 130.90 122.00 139.80 150.80 1102 27 3854 
Uric Acid (mg/dL) Yes 5.32 5.24 5.41 1.45 1158 0.4 13.4 0.002 No 5.13 5.04 5.22 1.49 1102 1.8 13.9 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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4.3.2.3 Logistic Regression  
 
Table 31: Logistic Regression for Paranitrophenol. 
 
  
Detecta  
(DFb=1) 
Detect, Non-Hispanic White 
(DF=1) 
Detect, Female  
(DF=1) 
Age 
β=-0.005 
Wald χ2=8.78 
p=0.003 
OR=0.995 
  
Mexican American  
β=-0.0239 
Wald χ2=0.0863 
p=0.77 
OR=1.18 
 
Non-Hispanic 
Black  
β=-0.213 
Wald χ2=2.00 
p=0.158 
OR=0.976 
 
Other Hispanic  
β=0.183 
Wald χ2=4.96 
p=0.026 
OR=1.45 
 
Other  
β=0.242 
Wald χ2=2.39 
p=0.122 
OR-1.54 
 
Male   
β=0.227 
Wald χ2=36.82 
p<0.0001 
OR=1.57 
 a(Detect) =  Detectable Level of Biomarker in the Urine Sample, used as a reference 
category in the Model;  b(DF)= Degree of Freedom. Significant differences are highlight 
in Bold. 
 
The overall model fit was significant, with Likelihood χ2= 71.3, p <0.0001 and 
the R2Max =0.0316.  The Hosmer and Lemeshow goodness-of-fit test resulted in a χ2= 
16.01, p= 0.0414, indicating that the data from the independent variables did not fit the 
model well.  The listed detects at the row headers are the reference groups for each sub-
category. When stratifying for individual groups, age does not seem to have an effect on 
the detection of a biomarker (β=-0.005 and OR=0.995, p=0.003).  Other Hispanics 
(β=0.183 and OR= 1.45, p= 0.026) had a slightly higher change in the regression 
coefficient and a higher odds of having a detectable level of biomarker than Non-
Hispanic Whites (reference group).  Males had a higher change in the regression 
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coefficient and a higher odds of having a detectable level of biomarker than females 
(β=0.227 and OR= 1.57, p< 0.0001).  
 
4.4 Pyrethroid 
4.4.1 Pyrethroid Biomarker: 3-Phenoxybenzoic Acid (3-PBA) 
4.4.1.1 Descriptive Statistics 
The information covered in the following figures and tables characterizes the 
exposures to pyrethroids in the overall sample and in various subgroups. 
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Figure24: Comparison of Means for 3-Phenoxybenzoic Acid.  µg/l= Micrograms per 
Liter; µg/g= Micrograms per Gram. Adjusting for creatinine results in means (both 
geometric and arithmetic) that are lower than if using the concentration of the 3-PBA 
biomarker in urine (µg/L) alone.  Limit of Detection (LOD) for 3-PBA in sample was 0.1 
µg/L. 
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Table 32: Descriptive Statistics for 3-Phenoxybenzoic Acid. 
 
 Biomarker (µg/L)a    Creatinine Adjusted (µg/g)b  
 
Geometric 
 Mean 
Arithmetic  
Mean   
Geometric 
 Mean 
Arithmetic 
 Mean 
nc 3048 3048  N 3046 3046 
Mean 0.336 1.55  Mean 0.323 1.15 
LCLd 0.320 0.864  LCL 0.310 0.819 
UCLe 0.352 2.24  UCL 0.338 1.48 
SDf 3.70 19.31  SD 3.37 9.27 
P25g 0.110 0.110  P25 0.143 0.143 
P50h 0.300 0.300  P50 0.292 0.292 
P75i 0.740 0.740  P75 0.612 0.612 
P90j 1.73 1.73  P90 1.46 1.46 
P95k 3.38 3.38  P95 2.82 2.82 
Minl 0.07 0.07  Min 0.0201 0.0201 
Maxm 999.6 999.6  Max 421.8 421.8 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(n) = Number in 
Sample; d(LCL) = Lower Confidence Limit; e(UCL) = Upper Confidence Limit; f(SD) = 
Standard Deviation; g(P25) = Lower Quartile; h(P50) = Median; i(P75) = Upper Quartile; 
j(P90) = 90th Percentile; k(P95) =95th Percentile; l(Min) = Minimum m(Max) = Maximum 
 
 
Like the organophosphates, adjusting for creatinine results in means (both 
geometric and arithmetic) that are lower than if using the concentration of the biomarker 
in urine (µg/L).  While the maximum urinary biomarker concentration was 999.6 µg/L, 
the next two highest values in the dataset were 253.8 and 160 µg/L.  
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Figure 25: Comparison of Detectable Geometric Mean Concentrations for  
3-Phenoxybenzoic Acid.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
 
Table 33: Descriptive Statistics for Detectable Levels of 3-Phenoxybenzoic Acid. 
 
  GMc LCLd UCLe SDf Median ng 
Biomarker (µg/L)a 0.531 0.507 0.556 3.10 0.450 2359 
Creatinine Adjusted (µg/g)b 0.442 0.422 0.463 3.12 0.375 2359 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(GM) = Geometric 
Mean; d(LCL) = Lower Confidence Limit; e(UCL) = Upper Confidence Limit; f(SD) = 
Standard Deviation; g(n) = Number in Sample 
 
The geometric mean was determined for 77.4% of the individuals that had a 
detectable level of biomarker in their urine sample.  Based on this analysis, the geometric 
mean for only detectable levels of the biomarker was ~0.2 µg/L higher that the overall 
geometric mean.  
 
 
 
 
 
89 
4.4.1.2 Comparative Statistics 
 
Male and Female Geometric Mean Levels for 
3-Phenoxybenzoic Acid 
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Figure 26: Comparison of Geometric Mean Values of Males Versus Females for               
3-Phenoxybenzoic Acid.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram.  
Color-coded “*” indicates females are significantly different from males. 
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Table 34: Student’s t-test Comparing Geometric Means of Males Versus Females for 3-
Phenoxybenzoic Acid. 
 
Biomarker (µg/L)a        
 GMb LCLc UCLd SDe Median nf (D/ND)g Ph 
Male 0.341 0.319 0.365 3.58 0.320 1429 (1131/298) 0.514 Female 0.331 0.310 0.353 3.81 0.290 1619 (1228/391) 
Total      3048  
        
Creatinine Adjusted (µg/g)i        
 GM LCL UCL SD Median n p 
Male 0.278 0.261 0.296 3.38 0.250 1429 <0.0001 Female 0.370 0.349 0.392 3.31 0.325 1617 
Total      3046  
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram 
 
Females had a significantly higher geometric mean when compared to males 
when adjusting for creatinine (µg/g).  However, the significance is not present when 
using the unadjusted urinary concentration of the biomarker.  
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Figure 27: Comparison of Geometric Mean Values of Ethnic Groups for                         
3-Phenoxybenzoic Acid.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
Color-coded “****” indicates this groups is significantly different from all other groups. 
Color-coded “*” indicates these groups are significantly different from each other. 
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Table 35: One-Way ANOVA and Tukey Analysis Comparing Geometric Means of 
Ethnic Groups for 3-Phenoxybenzoic Acid. 
 
Biomarker (µg/L)a       
 GMb LCLc UCLd SDe nf (D/ND)g Ph 
Mexican American 0.284 0.047 0.520 3.34 767 (580/187) 
<0.0001 
Non-Hispanic Black*all 0.489 0.251 0.727 3.35 762 (667/95) 
Non-Hispanic White 0.298 0.083 0.513 3.91 1269 (920/349) 
Other Hispanic 0.320 -0.339 0.980 3.82 129 (103/26) 
Other 0.335 -0.434 1.10 4.32 121 (89/32) 
Total     3048  
       
Creatinine Adjusted (µg/g)i       
 GM LCL UCL SD n p 
Mexican American* 0.283 0.068 0.497 3.03 767 
0.0007 
Non-Hispanic Black* 0.367 0.148 0.585 3.08 761 
Non-Hispanic White 0.323 0.123 0.524 3.64 1268 
Other Hispanic 0.301 -0.339 0.942 3.71 129 
Other 0.367 -0.341 1.08 3.98 121 
Total     3046  
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram.   
*all Indicates that group is significantly different than all other groups.                                 
* Indicates that groups are significantly different from each other. 
 
Non-Hispanic blacks have a significantly elevated geometric mean when 
compared to the other ethnic groups when evaluating the unadjusted urinary 
concentration of the biomarker (µg/L).  When adjusting for creatinine (µg/g), only 
Mexican American and Non-Hispanic Blacks were significantly different. 
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Figure 28: Comparison of Geometric Mean Values of Age Groups for                               
3-Phenoxybenzoic Acid.  µg/l= Micrograms per Liter; µg/g= Micrograms per Gram. 
Color-coded “*” indicates which groups are significantly different from each other. 
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Table 36: One-Way ANOVA and Tukey Analysis Comparing Geometric Means of Age 
Groups for 3-Phenoxybenzoic Acid. 
 
Biomarker (µg/L)a       
 GMb LCLc UCLd SDe nf (D/ND)g Ph 
Children 0.349 0.047 0.650 3.71 580 (453/127) 
0.0742 Adolescent 0.363 0.169 0.556 3.40 749 (613/136) 
Adult 0.321 0.140 0.501 3.17 1719 (1293/426) 
Total     3048  
       
Creatinine Adjusted (µg/g)i       
 GM LCL UCL SD n p 
Children*** 0.418 0.139 0.697 3.43 580 
<0.0001 Adolescent*** 0.269 0.049 0.490 3.08 748 
Adult*** 0.321 0.159 0.483 3.43 1718 
Total     3046  
a(µg/L) = Micrograms per Liter; b(GM) = Geometric Mean; c(LCL) = Lower Confidence 
Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard Deviation; f(n) = Number in 
Sample; g(D/ND) = Number of Detects/Number of Non-Detects; h(p) = Level of 
Significance at p= 0.05 Level (Highlighted in Bold); i(µg/g) = Micrograms per Gram. 
*** Indicates that all three groups are significantly different from each other. 
 
Significant differences were present between all three age groups when adjusting 
for creatinine (µg/g); however there is no significance when evaluating the unadjusted 
urinary concentration of the biomarker (µg/L).  
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Figure 29: Graph of Arithmetic Mean Height for Detects Versus Non-Detects for                    
3-Phenoxybenzoic Acid, Ages 6-11.  cm= Centimeter. 
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Table 37: Student’s t-test Comparing Detects Versus Non-Detects for Arithmetic Mean 
of Height for 3-Phenoxybenzoic Acid. 
 
Age Detecta Mean (cmb) LCLc UCLd SDe nf pg 
6 Yes 120.2 118.7 121.7 6.14 66 0.415 
No 119 116.9 121.2 4.84 22 
7 Yes 127 125.5 128.4 6.36 77 0.081 
No 124.6 122.8 126.5 4.60 27 
8 Yes 132 130.2 133.9 7.85 69 0.441 
No 133.6 129.8 137.5 7.79 18 
9 Yes 137.4 135.9 138.9 7.30 91 0.346 
No 135.8 133 138.7 6.59 23 
10 Yes 143.6 141.8 145.5 7.19 60 0.809 
No 144.2 139.3 149 10.04 19 
11 Yes 152.7 151 154.4 8.11 89 0.154 
No 149.7 146.1 153.3 6.91 17 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(cm) = Centimeters; 
c(LCL) = Lower Confidence Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard 
Deviation; f(n) = Number in Sample; g(p) = Level of Significance at p= 0.05 Level  
 
There are no significant differences at the p < 0.05 level between detect and non-
detect urinary concentrations of 3-phenoxybenzoic acid when evaluating variations in 
children’s height.  
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Figure 30: Graph of Arithmetic Mean Height for Detects Versus Non-Detects for                
3-Phenoxybenzoic Acid, Ages 6-11.  Kg= Kilograms.  = Significantly different 
means. 
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Table 38: Student’s t-test Comparing Detects Versus Non-Detects for Arithmetic Mean 
of Weight for 3-Phenoxybenzoic Acid. 
 
Age Detecta Mean (Kgb) LCLc UCLd SDe nf pg 
6 Yes 23.72 22.62 24.81 4.45 66 0.672 
No 23.28 21.76 24.80 3.43 22 
7 Yes 28.61 27.03 30.18 6.90 76 0.009 
No 25.56 23.89 27.22 4.22 27 
8 Yes 32.91 30.35 35.46 10.56 68 0.597 
No 31.46 27.47 35.45 7.76 17 
9 Yes 34.88 32.85 36.91 9.64 89 0.867 
No 34.49 29.74 39.25 11.00 23 
10 Yes 40.56 37.32 43.80 12.54 60 0.412 
No 43.35 36.64 50.06 13.92 19 
11 Yes 51.79 47.73 55.84 19.03 87 0.408 
No 47.64 40.26 55.02 13.85 16 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(Kg) = Kilograms; 
c(LCL) = Lower Confidence Limit; d(UCL) = Upper Confidence Limit; e(SD) = Standard 
Deviation; f(n) = Number in Sample; g(p) = Level of Significance at p= 0.05 Level 
(highlighted in Bold) 
 
There is a significantly higher arithmetic mean height for the age 7 group that 
recorded a detect for the biomarker in urine as compared to those with a non-detect for 
the biomarker. 
 
 
 
 
 
 
 
 
 
 
 
99 
Table 39: 3-Phenoxybenzoic Acid Female Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 18.95 18.32 19.58 9.69 924 5 102 0.993 No 18.95 17.98 19.91 8.62 309 5 102 
Albumin (g/dL)j Yes 4.16 4.14 4.19 0.34 924 2.6 5 0.671 No 4.17 4.13 4.21 0.36 309 2.6 5 
Alkaline Phosphatase (U/L) Yes 82.87 80.07 85.66 43.33 924 30 424 0.036 No 77.54 73.40 81.67 36.92 309 24 330 
Aspartate Transaminase (U/L) Yes 21.62 21.12 22.12 7.80 924 7 114 0.442 No 21.94 21.30 22.57 5.64 309 9 57 
Bicarbonate (mmol/L)k Yes 22.84 22.70 22.97 2.14 924 16 29 0.104 No 23.08 22.82 23.35 2.38 309 17 29 
Bilirubin (mg/dL)l Yes 0.65 0.64 0.67 0.21 924 0.2 1.9 0.119 No 0.68 0.65 0.70 0.22 309 0.2 2.1 
Blood Urea Nitrogen (mg/dL) Yes 11.76 11.39 12.14 5.82 924 2 122 0.015 No 12.78 12.05 13.50 6.50 309 2 53 
Total Calcium (mg/dL) Yes 9.44 9.41 9.46 0.39 924 8.3 11 0.897 No 9.44 9.40 9.48 0.39 309 8.1 10.8 
Chloride (mmol/L) Yes 103.10 102.90 103.30 2.63 924 90 111 0.065 No 102.80 102.40 103.10 2.95 308 89 113 
Cholesterol (mg/dL) Yes 188.60 185.80 191.40 42.99 924 90 476 <.0001 No 200.20 195.00 205.40 46.65 309 91 348 
Creatinine (mg/dL) Yes 0.72 0.71 0.73 0.18 924 0.3 2.8 0.008 No 0.77 0.74 0.81 0.32 309 0.4 4.4 
γ Glutamyl Transferase (U/L) Yes 20.19 18.76 21.61 22.11 924 4 369 0.752 No 20.60 18.45 22.76 19.26 309 5 190 
Globulin (mg/dL) Yes 3.18 3.16 3.21 0.40 924 2.3 5.4 0.006 No 3.11 3.07 3.15 0.37 309 2.2 4.4 
Glucose (mg/dL) Yes 90.27 88.25 92.29 31.29 924 34 521 0.761 No 89.75 87.07 92.42 23.91 309 30 284 
Iron (mg/dL) Yes 81.67 79.28 84.06 37.04 924 8 268 0.135 No 85.35 81.05 89.64 38.37 309 7 249 
Lactate Dehydrogenase (U/L) Yes 129.60 127.90 131.30 26.73 923 51 329 0.035 No 134.00 130.30 137.60 32.68 309 58 470 
Osmolality (mmol/Kg)m Yes 275.40 275.10 275.80 5.26 924 248 310 0.881 No 275.50 274.80 276.20 6.23 309 252 305 
Phosphorus (mg/dL) Yes 3.99 3.95 4.02 0.58 924 2.3 6.1 0.401 No 3.95 3.90 4.01 0.53 309 2.3 5.6 
Potassium (mmol/L) Yes 3.99 3.97 4.01 0.33 924 2.6 6 0.733 No 3.98 3.94 4.02 0.36 309 2.9 5.3 
Total Protein (g/dL) Yes 7.35 7.32 7.38 0.49 924 5.9 9.5 0.056 No 7.29 7.23 7.34 0.48 309 5.5 9.1 
Sodium (mmol/L) Yes 138.30 138.20 138.50 2.44 924 124 145 0.329 No 138.20 137.90 138.50 2.74 309 125 147 
Triglycerides (mg/dL) Yes 116.10 110.50 121.70 86.44 924 23 1077 0.001 No 134.30 124.50 144.10 87.41 309 34 628 
Uric Acid (mg/dL) Yes 4.50 4.42 4.58 1.19 924 1.8 10.8 0.027 No 4.70 4.54 4.86 1.40 309 0.4 13.9 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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Table 40: 3-Phenoxybenzoic Acid Male Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 27.44 26.12 28.75 19.56 857 7 243 0.0004 No 23.78 22.23 25.32 11.82 227 8 102 
Albumin (g/dL)j Yes 4.38 4.36 4.40 0.30 857 2.1 5.3 0.772 No 4.39 4.35 4.43 0.33 227 3 5.1 
Alkaline Phosphatase (U/L) Yes 102.10 97.32 106.90 71.59 857 19 589 0.675 No 104.70 93.58 115.80 85.04 227 37 617 
Aspartate Transaminase (U/L) Yes 27.07 26.14 27.99 13.80 857 9 187 0.0003 No 24.71 23.83 25.59 6.71 227 12 61 
Bicarbonate (mmol/L)k Yes 23.98 23.84 24.12 2.06 857 15 29 0.255 No 24.17 23.87 24.48 2.33 227 17 30 
Bilirubin (mg/dL)l Yes 0.82 0.80 0.84 0.32 857 0.3 3.5 0.436 No 0.81 0.77 0.84 0.26 227 0.3 2 
Blood Urea Nitrogen (mg/dL) Yes 14.02 13.67 14.37 5.24 857 3 48 0.407 No 14.35 13.62 15.07 5.54 227 3 40 
Total Calcium (mg/dL) Yes 9.55 9.53 9.58 0.39 857 7.2 11.3 0.658 No 9.54 9.49 9.60 0.42 227 7.8 10.8 
Chloride (mmol/L) Yes 102.50 102.40 102.70 2.43 857 92 112 0.020 No 102.00 101.60 102.40 3.13 227 83 109 
Cholesterol (mg/dL) Yes 185.90 182.90 188.90 44.47 857 71 566 0.931 No 186.20 180.80 191.70 41.72 227 84 407 
Creatinine (mg/dL) Yes 0.96 0.94 0.98 0.26 857 0.4 4.4 0.317 No 0.98 0.95 1.01 0.26 227 0.5 2.5 
γ Glutamyl Transferase (U/L) Yes 31.21 28.93 33.49 34.03 857 6 482 0.076 No 27.79 24.77 30.81 23.11 227 6 183 
Globulin (mg/dL) Yes 3.09 3.06 3.12 0.43 856 2 5.9 0.009 No 3.01 2.95 3.07 0.46 227 1.6 4.5 
Glucose (mg/dL) Yes 95.09 93.53 96.65 23.30 857 58 317 0.641 No 96.70 90.09 103.30 50.55 227 67 707 
Iron (mg/dL) Yes 97.36 94.71 100.00 39.50 857 12 333 0.767 No 96.49 91.54 101.40 37.86 227 18 223 
Lactate Dehydrogenase (U/L) Yes 138.90 136.60 141.30 34.90 857 52 399 0.004 No 132.90 129.40 136.30 26.43 227 72 220 
Osmolality (mmol/Kg)m Yes 278.00 277.70 278.30 4.67 857 264 299 0.105 No 277.20 276.20 278.10 7.20 227 218 298 
Phosphorus (mg/dL) Yes 3.91 3.86 3.96 0.70 857 2.4 6.6 0.946 No 3.91 3.82 4.00 0.68 227 2.4 6.6 
Potassium (mmol/L) Yes 4.14 4.12 4.16 0.35 857 3.1 5.5 0.003 No 4.06 4.02 4.11 0.36 227 3.1 5.3 
Total Protein (g/dL) Yes 7.47 7.44 7.50 0.45 856 5.9 9.8 0.025 No 7.40 7.33 7.46 0.50 227 5.3 9 
Sodium (mmol/L) Yes 139.10 139.00 139.30 2.22 857 131 147 0.022 No 138.60 138.10 139.00 3.44 227 108 144 
Triglycerides (mg/dL) Yes 141.30 128.40 154.30 192.70 857 21 3854 0.372 No 154.10 129.70 178.50 186.40 227 28 2337 
Uric Acid (mg/dL) Yes 6.00 5.92 6.09 1.28 857 1.5 10.8 0.880 No 5.99 5.79 6.18 1.50 227 2.6 13.4 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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Table 41: 3-Phenoxybenzoic Acid Overall Biochemical t-test Comparisons. 
Biochemical Detecta Mean LCLb UCLc SDd ne Minf Maxg ph 
Alanine Transaminase (U/L)i Yes 23.03 22.30 23.77 15.83 1781 5 243 0.001 No 20.99 20.11 21.87 10.37 536 5 102 
Albumin (g/dL)j Yes 4.27 4.25 4.29 0.34 1781 2.1 5.3 0.803 No 4.27 4.23 4.30 0.36 536 2.6 5.1 
Alkaline Phosphatase (U/L) Yes 92.13 89.37 94.89 59.42 1781 19 589 0.299 No 89.04 83.66 94.42 63.40 536 24 617 
Aspartate Transaminase (U/L) Yes 24.24 23.71 24.77 11.42 1781 7 187 0.003 No 23.11 22.58 23.64 6.26 536 9 61 
Bicarbonate (mmol/L)k Yes 23.39 23.28 23.49 2.18 1781 15 29 0.171 No 23.54 23.34 23.75 2.42 536 17 30 
Bilirubin (mg/dL)l Yes 0.74 0.72 0.75 0.28 1781 0.2 3.5 0.755 No 0.73 0.71 0.75 0.25 536 0.2 2.1 
Blood Urea Nitrogen (mg/dL) Yes 12.85 12.59 13.11 5.66 1781 2 122 0.047 No 13.44 12.92 13.96 6.16 536 2 53 
Total Calcium (mg/dL) Yes 9.49 9.48 9.51 0.39 1781 7.2 11.3 0.596 No 9.48 9.45 9.52 0.41 536 7.8 10.8 
Chloride (mmol/L) Yes 102.80 102.70 102.90 2.55 1781 90 112 0.007 No 102.40 102.20 102.70 3.05 535 83 113 
Cholesterol (mg/dL) Yes 187.30 185.30 189.30 43.72 1781 71 566 0.001 No 194.30 190.40 198.10 45.12 536 84 407 
Creatinine (mg/dL) Yes 0.84 0.82 0.85 0.25 1781 0.3 4.4 0.112 No 0.86 0.83 0.89 0.31 536 0.4 4.4 
γ Glutamyl Transferase (U/L) Yes 25.49 24.14 26.84 29.00 1781 4 482 0.108 No 23.65 21.84 25.45 21.26 536 5 190 
Globulin (mg/dL) Yes 3.14 3.12 3.16 0.42 1780 2 5.9 0.001 No 3.07 3.03 3.10 0.41 536 1.6 4.5 
Glucose (mg/dL) Yes 92.59 91.30 93.88 27.83 1781 34 521 0.953 No 92.69 89.49 95.89 37.69 536 30 707 
Iron (mg/dL) Yes 89.22 87.40 91.03 39.03 1781 8 333 0.658 No 90.07 86.80 93.34 38.52 536 7 249 
Lactate Dehydrogenase (U/L) Yes 134.10 132.70 135.60 31.28 1780 51 399 0.692 No 133.50 130.90 136.10 30.17 536 58 470 
Osmolality (mmol/Kg)m Yes 3.95 3.92 3.98 0.64 1781 2.3 6.6 0.613 No 3.93 3.88 3.99 0.60 536 2.3 6.6 
Phosphorus (mg/dL) Yes 4.06 4.05 4.08 0.35 1781 2.6 6 0.008 No 4.02 3.99 4.05 0.36 536 2.9 5.3 
Potassium (mmol/L) Yes 7.41 7.39 7.43 0.47 1780 5.9 9.8 0.001 No 7.33 7.29 7.37 0.49 536 5.3 9.1 
Total Protein (g/dL) Yes 276.70 276.40 276.90 5.14 1781 248 310 0.144 No 276.20 275.60 276.80 6.70 536 218 305 
Sodium (mmol/L) Yes 138.70 138.60 138.80 2.37 1781 124 147 0.009 No 138.30 138.10 138.60 3.06 536 108 147 
Triglycerides (mg/dL) Yes 128.20 121.40 135.10 148.00 1781 21 3854 0.045 No 142.70 130.90 154.40 138.50 536 28 2337 
Uric Acid (mg/dL) Yes 5.22 5.16 5.29 1.44 1781 1.5 10.8 0.792 No 5.24 5.11 5.38 1.58 536 0.4 13.9 
a(Detect) = Detectable Level of Biomarker in the Urine Sample; b(LCL) = Lower 
Confidence Limit; c(UCL) = Upper Confidence Limit; d(SD) = Standard Deviation; e(n) = 
Number in Sample; f(Min) = Minimum; g(Max) = Maximum; h(p) = Level of Significance 
at p= 0.05 Level (highlighted in Bold); i(U/L) = Units per Liter; j(g/dL) = Grams per 
Deciliter; k(mmol/L) = Millimole per Liter; l(mg/dL) = Milligram per Deciliter; 
m(mmol/Kg) = Millimole per Kilogram 
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4.4.1.3 Logistic Regression 
Table 42: Logistic Regression for 3-Phenoxybenzoic Acid. 
 
  
Detecta  
(DFb=1) 
Detect, Non-Hispanic White 
(DF=1) 
Detect, Female  
(DF=1) 
Age 
β=-0.006 
Wald χ2=10.2 
p=0.001 
OR=0.994 
  
Mexican American  
β=-0.175 
Wald χ2=3.44 
p=0.064 
OR=1.09 
 
Non-Hispanic 
Black  
β=0.076 
Wald χ2=0.171 
p=0.679 
OR=1.4 
 
Other Hispanic  
β=0.630 
Wald χ2=33.5 
p<0.0001 
OR=2.43 
 
Other  
β=-0.273 
Wald χ2=2.46 
p=0.117 
OR=0.986 
 
Male   
β=0.0927 
Wald χ2=4.40 
p=0.036 
OR=1.2 
a(Detect) =  Detectable Level of Biomarker in the Urine Sample, used as a reference 
category in the Model;  b(DF)= Degree of Freedom. Significant differences are highlight 
in Bold. 
 
The overall model fit was significant, with Likelihood χ2= 84.8, p <0.0001 and 
the R2 Max =0.0418.  The Hosmer and Lemeshow goodness-of-fit test resulted in a χ2= 
7.59, p= 0.475, indicating that the data from the independent variables fit the model well.  
The listed detects at the row headers are the reference groups for each sub-category. 
When stratifying for individual groups, age does not seem to have an effect on the 
detection of a biomarker (β=-0.006 and OR=0.994, p= 0.001).  Other Hispanics (β=0.630 
and OR= 2.43, p< 0.0001) had a higher change in the regression coefficient and a higher 
odds of having a detectable level of biomarker than Non-Hispanic Whites (reference 
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group).  Males had a change in the regression coefficient and a higher odds of having a 
detectable level of biomarker than females (β=0.0927 and OR= 1.2, p= 0.036).   
 
4.5 Summary of Mean Biomarker Concentrations 
The summary of biomarker concentrations from this research are listed in Table 43. 
Table 43: Summary of Means for All Three Biomarkers. 
 Biomarker (µg/L)a       Creatinine Adjusted (µg/g)b   
  
Geometric 
Mean 
Arithmetic 
Mean   
Geometric 
Mean 
Arithmetic 
Mean DFc 
TCPyd 2.07 4.28   1.98 3.42 78.6% 
PNPe 0.37 1.16   0.35 0.90 53.1% 
3-PBAf 0.34 1.55   0.32 1.15 77.4% 
a(µg/L) = Micrograms per Liter; b(µg/g) = Micrograms per Gram; c(DF) = Detection 
Frequency; d(TCPy) = 3,5,6-Trichloropyridinol; e(PNP) = Paranitrophenol; f(3-PBA) = 3-
Phenoxybenzoic Acid 
 
The unweighted sample results from this study can be compared to the 
concentrations determined in other studies. Those studies are listed in Table 44. 
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Table 44: Summary of Results from Epidemiological Biomarker Studies. 
Author na Sample Source Metabolite DFb Central Tendency 
Adgate (2001) [61] 102 Minnesota  Child TCPy 93% GMc=6.4 µg/Ld; AMe= 9.2 µg/L 
Aprea (1999) [143] 42 General Population Italy TCPy 88% CAM
f=3.5 µg/gg 
Arcury (2007) [144] 60 Latino Age 1-6 
TCPy 83.3% GM=1.92 µg/L; CAGMh=2.38 µg/g 
PNP 90% GM=1.0 µg/L; CAGM= 1.25 µg/g 
3-PBA 40% NAi 
Barr (2005) [145] 1994 All TCPy 91% (weighted) GM=1.77 µg/L; CAGM=1.58 µg/g 
Barr (2010) [64] 
3048  
(3046 for 
CA) 
NHANES 1999-
2002 3-PBA 
75.4% 
(weighted) 
GM=0.318 µg/L; CAGM=0.324 
µg/g 
Berger-Preiss 
(2002) [147] 145 
Adults and 
Children 3-PBA 28% Mean=0.25 µg/L 
Berkowitz (2004) 
[108] 404 Pregnant Females TCPy NA 
Median=7.6µg/L; CA Median= 11.5 
µg/g 
Eskenazi (2004) 
[107] 488 
Pregnant Females 
in Agricultural 
Community 
TCPy 76.3% Median=3.3 µg/L 
PNP 54.4% Median= 0.5 µg/L 
Hill (1995) [147] 993 USA NHANES III TCPy 82% Mean=4.5 µg/L; CAM=3.1 µg/g 980 PNP 41% Mean=1.6 µg/L, CAM=1.2 ug/g 
Macintosh (2001) 
[148] 80 
NHEXAS- 
Maryland TCPy 96% GM=5.1 µg/L; CAGM= 4.5 ug/g 
Morgan 2005 [149] 
128 
Children 
TCP NA GM=5.2 ng/ml; Mean=7.3 ng/ml 
110 
(Creatinine)   CAGM 8 ng/mg; CAM= 10.5 ng/mg 
Naeher (2010) 
[150] 203 
Children          
Age 4-6 3-PBA 99.5% Mean=5.0 ug/L 
Olsson (2003) [151] 140 NA TCPy 56% GM= 9.7 µg/L  PNP 99% GM= 2.1 µg/L 
Panuwet (2008) 
[51] 
136 Thailand General 
Population 
PNP 99.3% GM= 2.8 µg/L; CAGM=2.1 µg/g 
104 TCPy 76.5% GM=1.7 µg/L; CAGM=1.3 µg/g 
118 3-PBA 86.8% GM=1.1 µg/L; CAGM=0.86 µg/g 
Panuwet (2009) 
[114] 207 
Thailand Age 12-
13 
PNP 98% GM=2.68 ng/ML; CAGM=3.07 µg/g 
  AM=4.07 ng/ml; CAAMj=3.81 µg/g 
TCPy 92% GM=2.35 ng/ml; CAGM=2.7 mg/g 
  AM=4.02 ng/ml; CAAM=3.74 mg/g 
3-PBA 47% GM=0.2 ng/ml; CAGM=0.23 µg/g 
  AM=1.0 ng/ml; CAAM=0.95 µg/g 
Steenland (2000) 
[102] 
65 
Termiticide 
Applicator 
(Recent App) 
TCPy NA Mean=629.5 µg/L; CAM= 331 µg/g 
40 Termiticide Applicator TCPy NA Mean= 119.0 µg/L; CAM= 55 µg/g 
52 Non-Exposed Control TCPy  Mean=6.2 µg/L; CAM=3µg/g 
Ueyama (2009) 
[152] 
448 Japanese General Population 
3-PBA  GM=0.29 µg/L; CAGM=0.4 µg/g 
  AM=0.63 µg/L; CAAM= 0.73 µg/g 
87 Japanese Farmers   GM=0.38 µg/L; CAGM=0.45 µg/g   AM=0.76 µg/L; CAAM=0.81 µg/g 
Ye (2008) [153] 9778 Mothers TCPy 100% GM=1.2 µg/L; CAGM=1.9 µg/g 
a(n) = Number in Sample; b(DF) = Detection Frequency; c(GM) = Geometric Mean; 
d(µg/L) = Micrograms per Liter; e(AM) = Arithmetic Mean; f(CAM) = Creatinine-
Adjusted Mean; g(µg/g) = Micrograms per Gram; h(CAGM) = Creatinine-Adjusted GM; 
i(NA) = Not Available; j(CAAM) = Creatinine-Adjusted AM 
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4.6 Biochemical Summary 
When examining significant alterations in overall biochemical concentrations 
across all three biomarkers, only two were significant: cholesterol and sodium.   
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Figure 31: Overall Cholesterol Levels Across All Three Biomarkers.  mg/dL= Milligram 
per Deciliter; TCPy= 3,5,6-Trichloropyridinol; PNP = Paranitrophenol; 3-PBA = 3-
Phenoxybenzoic Acid.  The clinical reference for serum levels of cholesterol are <200 
mg/dL for desirable [154]. Borderline high is defined as 200-239 mg/dL [154].  
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Sodium Level Across Biomarkers
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Figure 32: Overall Sodium Levels Across All Three Biomarkers.  mmol/L= Millimole 
per Liter; TCPy= 3,5,6-Trichloropyridinol; PNP = Paranitrophenol; 3-PBA = 3-
Phenoxybenzoic Acid.  The clinical reference range for serum sodium levels is 135-145 
mmol/L [154]. 
 
 
There were more significant findings when comparing the overall biochemical 
concentrations between the organophosphate pesticides: bicarbonate, cholesterol, 
osmolality and sodium.  None of the significantly different levels were above clinical 
reference values [154]. 
 
Stratification for gender removes most of the consistent significant findings.  The 
only gender specific significantly different biochemical concentrations across all three 
biomarkers was the cholesterol levels in females.   
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Cholesterol Levels for Females Across Biomarkers
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Figure 33: Female Cholesterol Levels Across All Three Biomarkers.  mg/dL= Milligram 
per Deciliter; TCPy= 3,5,6-Trichloropyridinol; PNP = Paranitrophenol; 3-PBA = 3-
Phenoxybenzoic Acid.  The clinical reference for serum levels of cholesterol are <200 
mg/dL for desirable [154]. Borderline high is defined as 200-239 mg/dL [154].  
 
 
Males did not have a consistent significant alteration for biochemicals across the 
biomarkers.  Differences were limited to a specific biochemical.   
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Chapter 5 
Discussion 
5.1 Evaluation of Research Hypotheses 
 To determine how well the results of this study supported the overall goals of this 
research, the postulated hypotheses will be examined below: 
 
Hypothesis 1: Biomonitoring data obtained from NHANES indicate the presence of 
background biomarkers of exposure in individuals from a sample of the general 
population. 
 
 Based on the analysis of the pesticide dataset, there is evidence that pesticide 
biomarkers are present in a sample of the US general population.  However, significant 
findings varied when examining the biomarker in urine versus correcting for dilution with 
creatinine.  Metabolism rates can vary among individuals [26, 128].  Dilution of urine 
may have an effect on the concentration of the biomarker.  Creatinine adjustment has 
been used to normalize analyte concentrations due to the relatively constant excretion rate 
of creatinine, reporting the result as a weight of analyte per gram of creatinine [155].  
Barr et al. (2005) suggests that there may be urine dilution variability between groups 
(gender, ethnicity and age) and suggests establishing and using reference ranges for 
creatinine concentrations for the individual being investigated, as those values may be a 
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more appropriate comparison [155].  Analysis of both urinary biomarker level and 
creatinine-adjusted levels should be conducted to determine if significance is eliminated 
or elucidated due to the correction with creatinine, as observed with some groups in this 
study. 
 
Hypothesis 2: Mean concentrations of biomarkers of exposure are homogeneous across 
the various subgroups of the sample indicating that no one subgroup is at an increased 
risk of an adverse health outcome.  
 
Upon examining the mean concentrations of the biomarkers for various subgroups 
in the study, the mean concentrations are not homogeneous, at least on the surface.  
Certain groups have a significantly higher mean concentration of the biomarker than 
other groups.  Variations in the mean concentrations for gender depended on whether or 
not the biomarker concentration in urine (µg/L) was used or whether it was corrected for 
dilution with creatinine (µg/g).  Mean biomarker of exposure concentrations in ethnicity 
groups were consistently significantly varied.  Non-Hispanic Blacks, followed by 
Mexican Americans, appeared to have significantly higher means than the other members 
of the group.  Children and, in some cases, adolescents had significantly higher mean 
values as compared to adults.  These variations could be due to the biological differences 
between children and adults, as children may metabolize xenobiotics at a different rate 
than adults [156-157].  Different rates of enzyme activity may also affect these results.  
Increased instances of hand-to-mouth and pica in children may also result in an increase 
in exposure and explain the findings in this research [108, 158-159]. 
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Significant outcomes discovered in this research could be due to the oversampling 
of minorities by NHANES researchers in the sample.  NHANES oversampled certain 
subgroups that were the target of a specific health interest [160].  In this study period, 
NHANES researchers oversampled “low-income persons, adolescents 12-19 years, 
persons 60+ years of age, African Americans and Mexican Americans” [131].  The 
survey oversampled to increase reliability and precision in the target population [160].  
The NHANES documentation does not give a specific reason for not oversampling other 
subgroups (citing “cost prohibitive” or “operationally not feasible” as reasons) [160].  
This oversampling of certain minority or at-risk groups can overestimate the true 
exposure.  Significant means discovered in this data may be negated if the groups had not 
been given special focus.  
 
If oversampling had not occurred, and/or if the unused weight supplied by the 
NHANES documentation for population-based analysis could accurately control for the 
oversampling, this significance may disappear and the groups may actually be 
homogenous for mean concentrations of biomarkers.  When assessing the population, the 
results are viewed as non-random and over sampled.  As the documentation for the 
NHANES data suggests, not using appropriate weights may lead to an over-estimate of 
actual exposure.  If this is the case, these data may be viewed as overestimating the actual 
concentration of the biomarker when comparing to a population.  The population levels 
may actually be lower.   
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Hypothesis 3: Urine sample data from NHANES reveal that biomarker levels in the 
sample are not correlated with an increased risk of a negative health outcome.  
 
 Based on the overall results of this study, there were no consistent results to 
suggest that exposed individuals had an increased risk of a negative health outcome.  
When comparing the weight and height of study participants ages 6-11, those with a 
recorded biomarker detect versus non-detect, many of the comparisons were not 
significant, indicating that there was no appreciable difference between the exposed 
versus non-exposed.  No significant results were found when evaluating these differences 
for 3,5,6-trichloropyridinol exposure.  Paranitrophenol associated with shorter children at 
age 8 [Non-Detect=134.3 cm and Detect: 130.9 cm (p=0.046)] and taller children at age 
11 [Detect=153.7 cm and Non-Detect=149.9 cm (p=0.022)].  Heavier children associated 
with 3-Phenoxybenzoic Acid at age 7: [Detect=28.61 kg and Non-Detect=25.26 kg 
(p=0.009)].  The significant findings are not consistent between all of the exposed groups.  
Out of the 36 height and weight comparisons made between detectable levels of 
biomarker and non-detectable levels, 33 did not have significant findings at the p < 0.05 
level.  It appears that exposure in this group of children does not have an overall negative 
association with childhood development.  Similar comparisons have been made when 
evaluating biomarker levels in newborns with negative associations with birth outcomes 
[104, 107-108]. 
 
  The biochemical concentrations evaluated in this research can be used to evaluate 
health status at the time of the sampling.  Many of the comparisons were not statistically 
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significant.  For those levels that were significantly different, those groups with a detect 
for the biomarker were within the normal range.  While stratification for gender further 
elucidated any statistical significance between those with a detectable level of the 
biomarker versus those without a detectable level, few alterations were consistent across 
all three biomarkers, or among the biomarkers themselves.  The overall biochemical 
concentrations that had significant findings were cholesterol and sodium.  In females, the 
only consistently significantly different biochemical concentration was cholesterol.   
 
Overall, individuals that recorded a detect for the biomarker had a significantly 
lower cholesterol level than those without a detect.  While establishing a causal 
relationship is difficult without further investigation, it is possible that those individuals 
that ate more agricultural commodities had a healthier diet than those that did not have a 
detect for the biomarker.  If a major pathway of exposure to the general population is 
through the ingestion of residues on fruits and vegetables, then this conclusion may be 
plausible.  However, like the assessment of the biomarkers, the biochemical 
concentrations are one point in time and do not give a trend to evaluate variations in the 
levels.  Many factors can influence the status of biochemical levels on a physiological 
level and further research would be necessary to determine if there is a causal relationship 
[77].  
 
The logistic regression performed in this study allowed for modeling to determine 
how the independent variables (age, ethnicity and gender) had an effect on the detection 
of the biomarkers in the sample.  This was then used to determine, based on the detection, 
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which groups had a higher correlation/odds of having a detect for a biomarker when 
related to a reference group. Unlike linear regression, logistic regression does not fully 
explain the variance of the data.  Some groups within each biomarker had a significantly 
higher correlation and higher odds of having a detect.  All models were significant; 
however, only 3,5,6-trichloropyridinol and 3-phenoxybenzoic acid were the regressions 
where the independent variables fit the model well.  The independent variables did not fit 
well within the paranitrophenol model.  The independent variables for ethnicity and 
gender in the 3,5,6-trichloropyridinol model reflected the actual odds ratios well.  Gender 
consistency reflected the actual odds ratios for all models.   
 
5.2 Evaluation of Results 
Based on the information in Tables 43 and 44, the mean biomarker levels from 
this study are consistent with measurements of central tendency in other population and 
sample based research studies.  Comparison to other studies can be difficult depending on 
the statistical test performed or the sample media used, and, as previously noted, 
creatinine concentrations can vary for a variety of biological reasons.  The presentation of 
the data using multiple forms of descriptive and comparative statistics can make 
comparison to other studies more plausible. 
 
 Data from this NHANES dataset has been partially analyzed previously by Barr et 
al. in 2010 [64].  The study focused on 3-PBA and used data from both the 1999-2000 
and 2001-2001 NHANES data. The study divided participants into only three ethnic 
groups (Non-Hispanic White, Non-Hispanic Black and Hispanic Americans).  The Barr 
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et al. study used the sample weights found in the NHANES dataset.  Weighted geometric 
mean for the biomarker in urine was determined to be 0.318 µg/L and the creatinine 
adjusted geometric mean concentration was 0.324 µg/g [64].  Unweighted geometric 
means from the current research were 0.336 µg/L for the biomarker and 0.323 µg/g when 
correcting for creatinine.  When comparing the data in this research to the Barr et al. 
study in which the various weights and unequal probabilities of selection as supplied in 
the NHANES data files were integrated into the analysis, the unadjusted results only 
overestimate the means by 0.018 µg/L for the biomarker in urine and 0.001µg/g when 
adjusted for creatinine, suggesting that the results of the unadjusted data reflect the results 
of the complex study-designed data rather well. 
 
Based on occupational studies, individuals working with pesticides had a chronic 
exposure and measurable levels of biomarker in their urine.  The mean TCPy levels in the 
Albers et al. (2004) study were ~100 times higher than the mean TCPy concentration 
found in the current research [101].  The overall lack of significant findings in the Albers 
et al. study suggest that the individuals in this sample are at less risk of a negative 
neurological outcome.  In addition, the lack of consistency in the studies evaluating 
exposures and negative birth outcomes gives further support to the final hypothesis of 
this research.  There does not appear to be a consistent correlation between the low-levels 
observed in this research and an increased risk of an adverse health effect.  
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5.3 Biomarker of Exposure Research 
 As mentioned earlier in the literature review, epidemiological studies by Whyatt 
et al. (Columbia Study), Eskenazi et al. (CHAMACOS) and Berkowitz et al. (Mount 
Sinai Study) evaluated prenatal exposures to pesticides and negative birth outcomes [104, 
107-108].  Results across these studies were not consistent.  The Columbia Study 
indicated an association between chlorpyrifos exposure and reductions in birth weight 
and length [104].  Further analysis of the Columbia data by Rauh et al. suggested delays 
in neurodevelopment [105-106].  The studies by Eskenazi et al. and Berkowitz et al. did 
not find overall significant associations, and in some instances, some associations 
appeared to be protective [107-108]. 
 
Eaton et al., in a review of these studies, observed that other environmental 
factors, including tobacco and alcohol consumption, have been associated with negative 
birth outcomes in other studies and could have resulted in the negative outcomes 
discovered in the Columbia study [77].  While the cotinine levels of participants in the 
study were evaluated, the short half-life of the biomarker and the time of sample 
collection (after admission to the hospital) could have resulted in cotinine levels that 
underestimated actual exposure [77].  Additionally, alcohol consumption was self 
reported at the time of the interview and, while they were used as a covariate in the 
analysis in some part, underreporting of alcohol use could introduce bias into the 
evaluations.  Another limitation of these studies is the use of TCPy as the specific 
biomarker for chlorpyrifos. It has been determined that chlorpyrifos-methyl is also a 
parent of this biomarker [77].  Degradation of the parent compound in the environment 
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can also lead to TCPy exposure [148].  Because of the multiple sources of TCPy, the 
exposure to AChE inhibiting chlorpyrifos may be overestimated in certain instances.  
With regard to adverse health effects from prenatal exposure, Eaton et al. point out that 
scientific evidence does not suggest adverse neurodevelopment effects in infants from in 
utero dietary exposures to chlorpyrifos, if the neurodevelopment effects are from 
inhibition of AChE [77].  The article does point out that the results from studies finding 
associations cannot be ignored and further epidemiological investigation is warranted to 
fully elucidate the associations [77].   
 
The studies evaluating developmental effects from prenatal pesticide exposure 
attempted to associate low-level exposures with the risk of a negative health outcome.  
The results are determined by a cross-sectional examination with simultaneous evaluation 
of both exposure and outcome.  While this method may elucidate associations, these 
associations cannot be viewed as causal.  No studies were identified that attempted to 
characterize exposure over a period of time (none more than a few days or multiple 
sampling events over a period of time) with negative health effects.  A longitudinal 
prospective study may allow urinary biomarker concentrations to be better characterized.  
However, because other chemicals are capable of causing teratogenic and neurotoxic 
outcomes, controlling for the many covariates that are involved in everyday life may be 
difficult.   
 
In recent evaluations of exposures to pesticides, an increased amount of 
consideration has been placed on the small number of human studies that found 
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associations between prenatal pesticide exposures and negative birth outcomes, including 
those studies associating chlorpyrifos exposure and reductions in birth outcomes and 
cognitive abilities later in life.  While chlorpyrifos is still applied on a limited number of 
agricultural commodities, no recent studies were identified that attempted to re-evaluate 
current chlorpyrifos exposures and negative health effects.  Recently published articles 
appear to be based on original, decade-old cross-sectional data and use various analytical 
techniques and different covariates to determine if any associations can be found.  
Because chlorpyrifos is no longer registered for residential application, the current 
primary exposure route of exposure is oral.  Previous studies included evaluation of 
cumulative exposures.  If inhalation is no longer a viable exposure route for residential 
application (except for certain populations residing in close proximity to applications in 
agricultural scenarios), it would be expected that the current exposure is lower than those 
previously documented.  
 
 Many of the reviewed cross-sectional studies did not evaluate the dose that lead to 
the detection of the biomarkers in urine.  A small sample of studies were identified that 
attempted to estimate dose based on urinary concentrations of pesticide biomarkers.  
Fenske et al. (2000) used a deterministic steady state model to estimate doses from 
urinary concentrations of non-specific OP biomarkers [162].  The spray season 
creatinine-adjusted dose estimated means were 2.4 to 3.8 µg/kg/day for children with a 
household relation working in the agricultural field and the single day dose estimated 
creatinine-adjusted means ranged from 2.5-4.0 µg/kg/day [162].  A second study by 
Curwin et al. (2007) used a farming community and reference community in Iowa to 
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estimate a maximum-likelihood geometric mean chlorpyrifos dose of 0.67 µg/kg/day and 
a maximum dose estimate of 1.96 µg/kg/day [163].  The ATSDR exposure levels from 
Table 4 for chlorpyrifos put the acute and intermediate threshold dose at 3 µg/kg/day and 
the chronic dose at 1 µg/kg/day.  The average estimate of 0.67 µg/kg/day from the 
Curwin et al. study is below the chronic threshold dose and the estimated maximum is 
lower than the acute and intermediate threshold.  Because these are estimates, the actual 
exposed amount may be lower.  
 
Biological Exposure Indices published by the ACGIH established thresholds for 
biomarkers in occupational settings [55].  However, there are no regulatory health-related 
thresholds for pesticide biomarkers of exposure in the general population.  An attempt 
has been made by the German Human Biomonitoring Commission to establish a 
reference value (RV95) from biomonitoring data [164].  Heudorf et al. (2006) reports on 
the use of biomonitoring data from a sample of the German population for non-specific 
OP biomarkers and biomarkers for pyrethroids [165].  A threshold value was established 
for 3-PBA and was set at 2µg/L (for children age 3-14).  The RV95 were statistically 
derived from the 95% percentile within the 95% CI, are not based on toxicological data 
and are not related to risk assessment [165].  Because these levels are statistically 
derived, they should not be used to evaluate adverse health effects from biomonitoring 
data [164-165].  The RV95 is suggested to be used to determine if any one group or 
population is exposed to a higher degree than another population and to highlight 
populations for further evaluations where the biomarker levels are elevated.  The mean 
value for children age 6-11 in this study fall below this value.  
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Based on a Pubmed/Medline literature search, it appears research co-authored by 
Perera at the Columbia Center for Children’s Environmental Health has focused on 
children’s prenatal and postnatal exposure to various chemicals and the associated 
negative developmental outcomes.  In addition to pesticides, research at the Columbia 
Center has associated negative birth outcomes with prenatal exposures to polychlorinated 
biphenyl ethers (PCBEs) and polycyclic aromatic hydrocarbons (PAHs) [166-167].  The 
research findings from the Columbia center suggest two possibilities: 1) that the 
researchers suffer from investigator bias, because they continue to find negative 
associations between exposure to a variety of chemicals and birth outcomes, or 2) that 
their research is supporting the fact that there are multiple confounding chemicals that 
should be considered when investigating negative outcomes and that attributing negative 
outcomes to pesticides alone is not warranted.  It is the unknown exposures that hamper 
the establishment of causation in biomonitoring exposures scenarios. 
 
5.4 Evaluation of Risk 
The FQPA of 1996 required all routes of exposure to be taken into consideration 
when evaluating risk from a non-occupational exposure to pesticides [68].  This has 
resulted in the EPA publishing a guidance document on cumulative risk assessment for 
pesticides.  The cumulative risk assessment makes the assumption that the pesticides 
included in the assessment have a common mechanism of toxicity [168].  Because 
biomonitoring is an assessment based on all routes of exposure, the cumulative risk 
assessment is the most appropriate assessment for the current studies researching 
cumulative exposure data.  In 2006, the EPA published an updated cumulative risk 
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assessment for OP pesticides (an update to the original CRA published in 2002) [169].  
This assessment uses a relative potency factor (RPF) to determine joint risk associated 
with the exposure by using a reference chemical for comparing the toxicity of other OP 
pesticides [169].  The RPF is the ratio of the toxic potency of an OP to its index chemical 
(for the EPA CRA, the reference chemical is Methamidophos) [169].  This index 
pesticide is used to determine toxic potencies and used an exponential dose-response 
model to determine points of departure (POD) to extrapolate risk from an exposure in 
human populations [168].  The point of evaluation is the Benchmark Dose (BMD10) in 
which 10% AChE inhibition takes place in the female rat brain from an oral exposure 
[169].  This leads to the determination of a Margin of Exposure (MOE).  The target MOE 
is 100 for both one day acute exposure and for a 21 day rolling chronic exposure.  The 
findings from the CRA conclude that:  
“Taking all of these factors into account, EPA finds that there is a 
reasonable certainty of no harm to all major, identifiable 
population subgroups from cumulative exposure to the OPs” 
[169]. 
 
A recently published CRA for pyrethroids and pyrethrins finds that there are no 
cumulative estimated risks of concern [169].  These CRA are based on traditional 
outcomes from exposure to pesticides.  For the pyrethroid CRA, deltametrhin was used as 
the index chemical [169].  The findings from these CRA are designed to be conservative 
estimates of risk.  This conservative approach adds additional levels of safety into the 
findings of the assessments.   
 When reviewing the EPA Integrated Risk Information System (IRIS) database, it 
was observed that the previous Reference Dose (RfD) of 0.3µg/kg/day for chlorpyrifos 
had been removed on March 24, 2011 [170].  The RfD remains for both MP and 
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parathion.  It was not clear why the RfD was removed.  It may be because the RfD for 
chlorpyrifos is undergoing re-assessment based on the most recent risk assessment and 
Interim Registration Eligibility Decision (IRED).  The Oral RfD for permethrin remains 
at 5.0 x 10-2 mg/kg/day [171]. 
 
 The data obtained from biomonitoring is difficult to relate to risk due to the lack 
of information on exposure pathway and source of exposure [30].  Information on dose, 
duration of the exposure, phenotypic and genotypic differences between individuals and 
the time of the exposure in relation to the biomarker’s half-life are important to know 
when assessing toxicity [29].  However, this information is usually not available for 
large-scale biomonitoring programs and lack of such information can confound the 
results.  The detection of a biomarker from a biomonitoring event does not mean that the 
exposed are at an increased risk [29].  There is a dose for a particular chemical at which 
there will not be an appreciable risk of an adverse health effect. 
 
 While various biomonitoring studies have evaluated the presence of biomarkers in 
biological media, many shy away from assessing risk and suggest that the results serve as 
a reference range and can be used to evaluate trends in public health [29, 145, 147].  
However, previously mentioned studies have used biomonitoring data to form 
associations between low-level pesticides and negative birth outcomes.  Statistically 
significant associations were observed in the reviewed epidemiological studies as well as 
in the current research.  While associations may warrant further investigation, there are 
no known exposure factors in the current epidemiological biomonitoring studies that may 
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allow the elucidation of causality.  This research, like other cross-sectional research 
studies, evaluated the exposure and the outcome simultaneously.  Without knowing all of 
the covariates involved in the exposure, it remains difficult to relate the biomarker 
concentration to a risk factor.  
 
5.5 Limitations of the Research 
 It is unknown if the associations found in this research are causal based on the 
supplied information.  A more accurate way to identify health risk would be a 
longitudinal study [29].  This would assist in establishing a temporal relationship.  
However, this design also has limitation beyond normal bias.  The mechanism for the 
purported adverse health effects from chronic, low-level exposure, if it exists, is unknown 
and thus makes evaluating the dose-response relationship difficult.   
 
 Statistical comparisons were made in this research between detectable and non-
detectable levels of biomarkers of exposure in urine.  It is plausible that the individuals 
with a recorded non-detect were actually exposed, but those exposures were not detected 
due to the half-life of the biomarker and the laboratory limit of detection.  This could 
have introduced misclassification bias into the research.  However, this bias would be 
expected in other epidemiological studies using the same criteria.  The oversampling of 
certain subgroups may have introduced sampling bias into the analysis as well.   
 
 
123 
 
 
 
Chapter 6 
Conclusion 
This research study used urinary biomarker of exposure levels from the 2001-
2002 National Health and Nutrition Examination Survey (NHANES) national sampling 
event to determine if chronic, low-level exposure to pesticides can be associated with an 
appreciable increase in risk of an adverse health event.  The research determined that 
there were detectable levels of pesticide biomarkers in the urine of individuals that 
participated in the study, and, depending on the dilution of the analyte concentration in 
urine, certain subgroups had significantly higher means than others.  Analysis of 
phenotypic variations in children and adolescents and biochemical concentrations across 
individuals in the study revealed significant differences, but the differences were not 
consistent across the biomarkers.  Out of the 36 height and weight comparisons made 
between detectable levels of biomarker and non-detectable levels, 33 did not have 
significant findings, and two of the associations indicated that detection of a biomarker in 
urine was positively associated with the height and weight of children.   Mean overall 
biomarker levels were consistent with other studies evaluating background levels of 
pesticides and the mean levels were lower than those in research that associated negative 
outcomes from exposure.  In instances where significant differences between biochemical 
concentrations where found, the group with detectable levels of a biomarker did not 
exceed established clinical reference values.  In fact, cholesterol levels for overall 
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biomarker concentration and females were consistently and significantly lower than those 
with a non-detect for the biomarker.  
 
As previously noted, based on the weight of evidence from the studies 
investigating low levels of biomarkers of exposure in biological media, there are not 
enough significant findings to conclude that these exposures would result in adverse 
health effects or increase the risk of such outcomes.  While young individuals may be 
more sensitive to AChE inhibition from acute exposures, there is little evidence to 
suggest that the pesticides examined in this research bioaccumulate in any body 
compartment [75].  Metabolism and elimination of the parent compound and 
intermediates appears to occur quickly [75, 120]. 
 
 Biomarker of exposure concentrations from national sampling events can be 
useful for establishing ranges of background exposures, but only if the data is unbiased.  
Oversampling of certain subpopulations can skew the results and give an inaccurate 
baseline for evaluation.  Additionally, the physical sampling locations for the national 
sampling should be made available to determine if one area has an elevated exposure 
level as compared to another. 
 
 Any further studies investigating low-level pesticide exposures and 
neurodevelopment impairment should seek to further limit investigator bias that skews 
the research results.  Conducting research with a pre-conceived notion that exposures to 
pesticides, and other chemicals, will be associated with negative outcomes can have an 
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effect on results and can negatively influence any regulatory decisions based on those 
results.   
 
Conclusions from this study are: 
1. Biomarkers of exposure are present in a sample of the US population and certain 
subgroups have significantly higher geometric means than others. 
2. Due to the cross-sectional nature of the data, there is no clear way of establishing 
causation based on the associations found. 
3. Oversampling of certain at-risk groups may have skewed the findings in the 
research. 
4. Evaluation of health status of the individuals in the sample does not indicate that 
there is an overall negative health impact associated with exposures. 
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